<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ARIMIDEXÂ - anastrozoleÂ tabletÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ARIMIDEX safely and effectively. See full prescribing information for ARIMIDEX. <br>ARIMIDEXÂ® (anastrozole) tablet for oral use <br>Initial U.S. Approval: 1995</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ARIMIDEX is an aromatase inhibitor indicated for: </p>
<p class="Highlighta">â€¢ Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer (<a href="#rowellsl1186580838410">1.1</a>) </p>
<p class="Highlighta">â€¢ First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer (<a href="#rowellsl1186580858676">1.2</a>) </p>
<p class="Highlighta">â€¢ Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX (<a href="#rowellsl1186580880207">1.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">One 1 mg tablet taken once daily (<a href="#rowellsl1186580931221">2.1</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">1 mg tablets (<a href="#rowellsl1231180734086">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">â€¢ Women of premenopausal endocrine status, including pregnant women (<a href="#rowellsl1231180592931">4.1</a>, <a href="#rowellsl1231180632025">8.1</a>) </p>
<p class="Highlighta">â€¢ Patients with demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ARIMIDEX or any excipient (<a href="#rowellsl1231180831679">4.2</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">â€¢ In women with pre-existing <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, an increased incidence of ischemic cardiovascular events occurred with ARIMIDEX use compared to tamoxifen use. Consider risks and benefits. (<a href="#rowellsl1186581032719">5.1, 6.1</a>) </p>
<p class="Highlighta">â€¢ Decreases in bone mineral density may occur. Consider bone mineral density monitoring. (<a href="#rowellsl1186582726687">5.2</a>, <a href="#rowellsl1231180697883">6.1</a>) </p>
<p class="Highlighta">â€¢ Increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> may occur. Consider <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> monitoring. (<a href="#rowellsl1186582726687">5.3</a>, <a href="#rowellsl1231180697883">6.1</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In the early breast cancer (ATAC) study, the most common (occurring with an incidence of &gt;10%) side effects occurring in women taking ARIMIDEX included: <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> and <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span>, regardless of causality. (<a href="#rowellsl1186582828732">6.1</a>) </p>
<p class="Highlighta">In the advanced breast cancer studies, the most common (occurring with an incidence of &gt;10%) side effects occurring in women taking ARIMIDEX included: <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. (<a href="#rowellsl1186582828732">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">â€¢ Tamoxifen: Do not use in combination with ARIMIDEX. No additional benefit seen over tamoxifen monotherapy. (<a href="#rowellsl1186587126555">7.1</a>, <a href="#rowellsl1186587126555">14.1</a>). </p>
<p class="Highlighta">â€¢ Estrogen-containing products: Combination use may diminish activity of ARIMIDEX. (<a href="#rowellsl1231180890007">7.2</a>). </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">â€¢ Pediatric patients: Efficacy has not been demonstrated for pubertal boys of adolescent age with <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> or girls with McCune-Albright Syndrome and progressive <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>. (<a href="#rowellsl1231180931523">8.4</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1  Adjuvant Treatment</a></h2>
<h2><a href="#section-1.2" class="toc">1.2  First-Line Treatment</a></h2>
<h2><a href="#section-1.3" class="toc">1.3  Second-Line Treatment</a></h2>
<h1><a href="#section-2" class="toc">2   DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS </a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Pregnancy and Premenopausal Women</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Ischemic Cardiovascular Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Bone Effects</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7   DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Tamoxifen</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Estrogen</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Warfarin</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Cytochrome P450</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14   CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adjuvant Treatment of Breast Cancer in Postmenopausal Women</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Second-Line Therapy in Postmenopausal Women with Advanced Breast Cancer who had Disease Progression following Tamoxifen Therapy</a></h2>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">Storage</a></h2>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Pregnancy</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>) Reactions</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Ischemic Cardiovascular Events</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Bone Effects</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6 Tamoxifen</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186580838410"></a><a name="section-1.1"></a><p></p>
<h2>1.1  Adjuvant Treatment</h2>
<p class="First">ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186580858676"></a><a name="section-1.2"></a><p></p>
<h2>1.2  First-Line Treatment</h2>
<p class="First">ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186580880207"></a><a name="section-1.3"></a><p></p>
<h2>1.3  Second-Line Treatment</h2>
<p class="First">ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.   Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="rowellsl1186580931221"></a><a name="section-2"></a><p></p>
<h1>2   DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1231183533193"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dose</h2>
<p class="First">The dose of ARIMIDEX is one 1 mg tablet taken once a day.  For patients with advanced breast cancer, ARIMIDEX should be continued until <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span>. ARIMIDEX can be taken with or without food.</p>
<p>For adjuvant treatment of early breast cancer in postmenopausal women, the optimal duration of therapy is unknown.  In the ATAC trial, ARIMIDEX was administered for five years [see <span class="Italics">Clinical Studies (<a href="#rowellsl1186587182242">14.1</a>)</span>].  </p>
<p>No dosage adjustment is necessary for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or for elderly patients [see <span class="Italics">Use in Specific Populations (<a href="#rowellsl1186580997361">8.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186587366238"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </h2>
<p class="First">No changes in dose are recommended for patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  ARIMIDEX has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics">Use in Specific Populations (<a href="#rowellsl1186580971002">8.7</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="rowellsl1231180734086"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS </h1>
<p class="First">The tablets are white, biconvex, film-coated containing 1 mg of anastrozole. The tablets are impressed on one side with a logo consisting of a letter â€œAâ€? (upper case) with an arrowhead attached to the foot of the extended right leg of the â€œAâ€? and on the reverse with the tablet strength marking â€œAdx 1â€?.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1231180592931"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Pregnancy and Premenopausal Women</h2>
<p class="First">ARIMIDEX may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. ARIMIDEX is contraindicated in women who are or may become pregnant. There are no adequate and well-controlled studies in pregnant women using ARIMIDEX. If ARIMIDEX  is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus or potential risk for loss of the pregnancy [see <span class="Italics">Use in Specific Populations (<a href="#rowellsl1231180632025">8.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1231180831679"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">ARIMIDEX is contraindicated in any patient who has shown a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to the drug or to any of the excipients. Observed reactions include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> [see <span class="Italics">Adverse Reactions (<a href="#rowellsl1231182451435">6.2</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186581032719"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Ischemic Cardiovascular Events</h2>
<p class="First">In women with pre-existing <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, an increased  incidence of ischemic cardiovascular events was observed with ARIMIDEX in the ATAC trial (17% of patients on ARIMIDEX and 10% of patients on tamoxifen).  Consider risk and benefits of ARIMIDEX therapy in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> [see <span class="Italics">Adverse Reactions (<a href="#rowellsl1231180697883">6.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>5.2  Bone Effects</h2>
<p class="First">Results from the ATAC trial bone substudy at 12 and 24 months demonstrated that patients receiving ARIMIDEX had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline. Patients receiving tamoxifen had a mean increase in both lumbar spine and total hip BMD compared to baseline [see <span class="Italics">Adverse Reactions (<a href="#rowellsl1231180697883">6.1</a>)</span> ].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186582726687"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></h2>
<p class="First">During the ATAC trial, more patients receiving ARIMIDEX were reported to have elevated serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> compared to patients receiving tamoxifen (9%Â versus 3.5%, respectively) [see <span class="Italics">Adverse Reactions (<a href="#rowellsl1231180697883">6.1</a>)</span> ].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Serious adverse reactions with ARIMIDEX occurring in less than 1 in 10,000 patients, are:  1) <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as lesions, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>; 2) <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, and/or throat. This may cause difficulty in swallowing and/or breathing; and 3) changes in blood tests of the liver function, including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the liver with symptoms that may include a general feeling of not being well, with or without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4009394" conceptname="Liver pain">liver pain</span> or liver <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> [see <span class="Italics">Adverse Reactions (<a href="#rowellsl1231182451435">6.2</a>)</span>]. </p>
<p>Common adverse reactions (occurring with an incidence of &gt;10%) in women taking ARIMIDEX included: <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span>.</p>
<p>In the ATAC trial, the most common reported adverse reaction (&gt;0.1%) leading to discontinuation of therapy for both treatment groups was <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, although there were fewer patients who discontinued therapy as a result of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> in the ARIMIDEX group.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1231180697883"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3>      Adjuvant Therapy</h3>
<p class="First"></p>
<p>Adverse reaction data for adjuvant therapy are based on the ATAC trial [see Clinical Studies (14.1)]. The median duration of adjuvant treatment for safety evaluation was 59.8 months and 59.6 months for patients receiving ARIMIDEX 1 mg and tamoxifen 20 mg, respectively. </p>
<p>Adverse reactions occurring with an incidence of at least 5% in either treatment group during treatment or within 14 days of the end of treatment are presented in Table 1.</p>
<a name="i55433b95-ca6c-4332-86de-f9b2132633ed"></a><table frame="hsides">
<caption><span>Table 1 â€” Adverse reactions occurring with an incidence of at least 5% in either treatment group during treatment, or within 14 days of the end of treatment in the ATAC trial 
                                 </span></caption>
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td align="left" valign="top">
<p class="First"><span class="Bold">Body system and adverse reactions by</span></p>
<p><span class="Bold">COSTARTpreferred term
                                             </span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">ARIMIDEX 1 mg</span></p>
<p><span class="Bold">(N<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> = 3092)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Tamoxifen 20 mg</span></p>
<p><span class="Bold">(N<a href="#footnote-1" class="Sup">*</a> = 3094)</span></p>
</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>N=Number of patients receiving the treatment.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="Bold">Body as a whole</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>		</p></td>
<td align="center" valign="top"><p class="First">575 (19)</p></td>
<td align="center" valign="top"><p class="First">544 (18)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td align="center" valign="top"><p class="First">533 (17)</p></td>
<td align="center" valign="top"><p class="First">485 (16)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td align="center" valign="top"><p class="First">321 (10)</p></td>
<td align="center" valign="top"><p class="First">309 (10)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="center" valign="top"><p class="First">314 (10)</p></td>
<td align="center" valign="top"><p class="First">249 (8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td align="center" valign="top"><p class="First">271 (9)</p></td>
<td align="center" valign="top"><p class="First">276 (9)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td align="center" valign="top"><p class="First">285 (9)</p></td>
<td align="center" valign="top"><p class="First">276 (9)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span></p></td>
<td align="center" valign="top"><p class="First">311 (10)</p></td>
<td align="center" valign="top"><p class="First">303 (10)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span></p></td>
<td align="center" valign="top"><p class="First">175 (6)</p></td>
<td align="center" valign="top"><p class="First">195 (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
<td align="center" valign="top"><p class="First">200 (7)</p></td>
<td align="center" valign="top"><p class="First">150 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">   Neoplasm</p></td>
<td align="center" valign="top"><p class="First">162 (5)</p></td>
<td align="center" valign="top"><p class="First">144 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">Cyst</span></p></td>
<td align="center" valign="top"><p class="First">138 (5)</p></td>
<td align="center" valign="top"><p class="First">162 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Cardiovascular</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">Vasodilatation</span></p></td>
<td align="center" valign="top"><p class="First">1104 (36)</p></td>
<td align="center" valign="top"><p class="First">1264 (41)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td align="center" valign="top"><p class="First">402 (13)</p></td>
<td align="center" valign="top"><p class="First">349 (11)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Digestive</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="center" valign="top"><p class="First">343 (11)</p></td>
<td align="center" valign="top"><p class="First">335 (11)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td align="center" valign="top"><p class="First">249 (8)</p></td>
<td align="center" valign="top"><p class="First">252 (8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="center" valign="top"><p class="First">265 (9)</p></td>
<td align="center" valign="top"><p class="First">216 (7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td align="center" valign="top"><p class="First">206 (7)</p></td>
<td align="center" valign="top"><p class="First">169 (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorder</span></p></td>
<td align="center" valign="top"><p class="First">210 (7)</p></td>
<td align="center" valign="top"><p class="First">158 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Hemic and lymphatic</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">Lymphedema</span></p></td>
<td align="center" valign="top"><p class="First">304 (10)</p></td>
<td align="center" valign="top"><p class="First">341 (11)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td align="center" valign="top"><p class="First">113 (4)</p></td>
<td align="center" valign="top"><p class="First">159 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Metabolic and nutritional</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>	</p></td>
<td align="center" valign="top"><p class="First">311 (10)</p></td>
<td align="center" valign="top"><p class="First">343 (11)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></p></td>
<td align="center" valign="top"><p class="First">285 (9)</p></td>
<td align="center" valign="top"><p class="First">274 (9)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span></p></td>
<td align="center" valign="top"><p class="First">278 (9)</p></td>
<td align="center" valign="top"><p class="First">108 (3.5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Musculoskeletal</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></p></td>
<td align="center" valign="top"><p class="First">512 (17)</p></td>
<td align="center" valign="top"><p class="First">445 (14)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td align="center" valign="top"><p class="First">467 (15)</p></td>
<td align="center" valign="top"><p class="First">344 (11)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></p></td>
<td align="center" valign="top"><p class="First">325 (11)</p></td>
<td align="center" valign="top"><p class="First">226 (7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span></p></td>
<td align="center" valign="top"><p class="First">315 (10)</p></td>
<td align="center" valign="top"><p class="First">209 (7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></p></td>
<td align="center" valign="top"><p class="First">201 (7)</p></td>
<td align="center" valign="top"><p class="First">185 (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Arthrosis</span></p></td>
<td align="center" valign="top"><p class="First">207 (7)</p></td>
<td align="center" valign="top"><p class="First">156 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">Joint Disorder</span></p></td>
<td align="center" valign="top"><p class="First">184 (6)</p></td>
<td align="center" valign="top"><p class="First">160 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td align="center" valign="top"><p class="First">179 (6)</p></td>
<td align="center" valign="top"><p class="First">160 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Nervous system</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td align="center" valign="top"><p class="First">413 (13)</p></td>
<td align="center" valign="top"><p class="First">382 (12)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td align="center" valign="top"><p class="First">309 (10)</p></td>
<td align="center" valign="top"><p class="First">281 (9)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="center" valign="top"><p class="First">236 (8)</p></td>
<td align="center" valign="top"><p class="First">234 (8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td align="center" valign="top"><p class="First">195 (6)</p></td>
<td align="center" valign="top"><p class="First">180 (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td align="center" valign="top"><p class="First">215 (7)</p></td>
<td align="center" valign="top"><p class="First">145 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Respiratory</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td align="center" valign="top"><p class="First">443 (14)</p></td>
<td align="center" valign="top"><p class="First">422 (14)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span></p></td>
<td align="center" valign="top"><p class="First">261 (8)</p></td>
<td align="center" valign="top"><p class="First">287 (9)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td align="center" valign="top"><p class="First">234 (8)</p></td>
<td align="center" valign="top"><p class="First">237 (8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td align="center" valign="top"><p class="First">184 (6)</p></td>
<td align="center" valign="top"><p class="First">159 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td align="center" valign="top"><p class="First">167 (5)</p></td>
<td align="center" valign="top"><p class="First">153 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Skin and appendages</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td align="center" valign="top"><p class="First">333 (11)</p></td>
<td align="center" valign="top"><p class="First">387 (13)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td align="center" valign="top"><p class="First">145 (5)</p></td>
<td align="center" valign="top"><p class="First">177 (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Special Senses</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataract Specified</span></p></td>
<td align="center" valign="top"><p class="First">182 (6)</p></td>
<td align="center" valign="top"><p class="First">213 (7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Urogenital</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">Leukorrhea</span></p></td>
<td align="center" valign="top"><p class="First">86 (3)</p></td>
<td align="center" valign="top"><p class="First">286 (9)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></p></td>
<td align="center" valign="top"><p class="First">244 (8)</p></td>
<td align="center" valign="top"><p class="First">313 (10)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></p></td>
<td align="center" valign="top"><p class="First">251 (8)</p></td>
<td align="center" valign="top"><p class="First">169 (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Breast Neoplasm</p></td>
<td align="center" valign="top"><p class="First">164 (5)</p></td>
<td align="center" valign="top"><p class="First">139 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">Vulvovaginitis</span></p></td>
<td align="center" valign="top"><p class="First">194 (6)</p></td>
<td align="center" valign="top"><p class="First">150 (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Hemorrhage</span>
                                          </p></td>
<td align="center" valign="top"><p class="First">122 (4)</p></td>
<td align="center" valign="top"><p class="First">180 (6)</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span></p></td>
<td align="center" valign="top"><p class="First">125 (4)</p></td>
<td align="center" valign="top"><p class="First">158 (5)</p></td>
</tr>
</tbody>
</table>
<p>Certain adverse reactions and combinations of adverse reactions were prospectively specified for analysis, based on the known pharmacologic properties and side effect profiles of the two drugs (see Table <a href="#rowellsl1231184163205">2</a>). </p>
<a name="rowellsl1231184163205"></a><table frame="hsides">
<caption><span>Table 2 â€” Number of Patients with Pre-specified Adverse Reactions in ATAC Trial
                                 </span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td align="left" valign="top"></td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">N=3092</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">N=3094</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td align="left" valign="top"><p class="First"><span class="Bold">Odds-ratio</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">95% CI</span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flashes</span></p></td>
<td align="left" valign="top"><p class="First">1104 (36)</p></td>
<td align="left" valign="top"><p class="First">1264 (41)</p></td>
<td align="left" valign="top"><p class="First">0.80</p></td>
<td align="left" valign="top"><p class="First">0.73 âˆ’ 0.89</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Musculoskeletal Events
                                          </p></td>
<td align="left" valign="top"><p class="First">1100 (36)</p></td>
<td align="left" valign="top"><p class="First">911 (29)</p></td>
<td align="left" valign="top"><p class="First">1.32</p></td>
<td align="left" valign="top"><p class="First">1.19 âˆ’ 1.47</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td align="left" valign="top"><p class="First"> 575 (19)</p></td>
<td align="left" valign="top"><p class="First">544 (18)</p></td>
<td align="left" valign="top"><p class="First">1.07</p></td>
<td align="left" valign="top"><p class="First">0.94 âˆ’ 1.22</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Mood Disturbances</p></td>
<td align="left" valign="top"><p class="First"> 597 (19)</p></td>
<td align="left" valign="top"><p class="First">554 (18)</p></td>
<td align="left" valign="top"><p class="First">1.10</p></td>
<td align="left" valign="top"><p class="First">0.97 âˆ’ 1.25</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="left" valign="top"><p class="First">393 (13)</p></td>
<td align="left" valign="top"><p class="First">384 (12)</p></td>
<td align="left" valign="top"><p class="First">1.03</p></td>
<td align="left" valign="top"><p class="First">0.88 âˆ’ 1.19</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">All <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></p></td>
<td align="left" valign="top"><p class="First">315 (10)</p></td>
<td align="left" valign="top"><p class="First">209 (7)</p></td>
<td align="left" valign="top"><p class="First">1.57</p></td>
<td align="left" valign="top"><p class="First">1.30 âˆ’ 1.88</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> of Spine, 	Hip, or Wrist</p></td>
<td align="left" valign="top"><p class="First">133 (4)</p></td>
<td align="left" valign="top"><p class="First">91 (3)</p></td>
<td align="left" valign="top"><p class="First">1.48</p></td>
<td align="left" valign="top"><p class="First">1.13 âˆ’ 1.95</p></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">	Wrist/Collesâ€™ 	<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span></p></td>
<td align="left" valign="top"><p class="First">67 (2)</p></td>
<td align="left" valign="top"><p class="First">50 (2)</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">	Spine <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span></p></td>
<td align="left" valign="top"><p class="First">43 (1)</p></td>
<td align="left" valign="top"><p class="First">22 (1)</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fractures</span></p></td>
<td align="left" valign="top"><p class="First">28 (1)</p></td>
<td align="left" valign="top"><p class="First">26 (1)</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span></p></td>
<td align="left" valign="top"><p class="First">182 (6)</p></td>
<td align="left" valign="top"><p class="First">213 (7)</p></td>
<td align="left" valign="top"><p class="First">0.85</p></td>
<td align="center" valign="top"><p class="First">0.69 âˆ’ 1.04</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></p></td>
<td align="left" valign="top"><p class="First">167 (5)</p></td>
<td align="left" valign="top"><p class="First">317 (10)</p></td>
<td align="left" valign="top"><p class="First">0.50</p></td>
<td align="center" valign="top"><p class="First">0.41 âˆ’ 0.61</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Ischemic Cardiovascular Disease</p></td>
<td align="left" valign="top"><p class="First">127 (4)</p></td>
<td align="left" valign="top"><p class="First">104 (3)</p></td>
<td align="left" valign="top"><p class="First">1.23</p></td>
<td align="center" valign="top"><p class="First">0.95 âˆ’ 1.60</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">Vaginal Discharge</span></p></td>
<td align="left" valign="top"><p class="First">109 (4)</p></td>
<td align="left" valign="top"><p class="First">408 (13)</p></td>
<td align="left" valign="top"><p class="First">0.24</p></td>
<td align="center" valign="top"><p class="First">0.19 âˆ’ 0.30</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic events</span></p></td>
<td align="left" valign="top"><p class="First">87 (3)</p></td>
<td align="left" valign="top"><p class="First">140 (5)</p></td>
<td align="left" valign="top"><p class="First">0.61</p></td>
<td align="center" valign="top"><p class="First">0.47 âˆ’ 0.80</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Deep Venous 	Thromboembolic 	Events</p></td>
<td align="left" valign="top"><p class="First">48 (2)</p></td>
<td align="left" valign="top"><p class="First">74 (2)</p></td>
<td align="left" valign="top"><p class="First">0.64</p></td>
<td align="center" valign="top"><p class="First">0.45 âˆ’ 0.93</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Ischemic Cerebrovascular Event</p></td>
<td align="left" valign="top"><p class="First">62 (2)</p></td>
<td align="left" valign="top"><p class="First">88 (3)</p></td>
<td align="left" valign="top"><p class="First">0.70</p></td>
<td align="center" valign="top"><p class="First">0.50 âˆ’ 0.97</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First">Endometrial Cancer
                                          </p></td>
<td align="left" valign="top"><p class="First">4 (0.2)</p></td>
<td align="left" valign="top"><p class="First">13 (0.6)</p></td>
<td align="left" valign="top"><p class="First">0.31</p></td>
<td align="center" valign="top"><p class="First">0.10 âˆ’ 0.94</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Ischemic Cardiovascular Events</span></p>
<p>	Between treatment arms in the overall population of 6186 patients, there was no statistical difference in ischemic cardiovascular events (4% ARIMIDEX vs. 3% tamoxifen). In the overall population, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> was reported in 71/3092 (2.3%) patients in the ARIMIDEX arm and 51/3094 (1.6%) patients in the tamoxifen arm; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was reported in 37/3092 (1.2%) patients in the ARIMIDEX arm and 34/3094 (1.1%) patients in the tamoxifen arm.  </p>
<p>In women with pre-existing <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> 465/6186 (7.5%), the incidence of ischemic cardiovascular events was 17% in patients on ARIMIDEX and 10% in patients on tamoxifen.  In this patient population, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> was reported in 25/216 (11.6%) patients receiving ARIMIDEX and 13/249 (5.2%) patients receiving tamoxifen; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was reported in 2/216 (0.9%) patients receiving ARIMIDEX and 8/249 (3.2%) patients receiving tamoxifen.</p>
<p><span class="Italics">Bone Mineral Density Findings</span></p>
<p>Results from the ATAC trial bone substudy at 12 and 24 months demonstrated that patients receiving ARIMIDEX had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline. Patients receiving tamoxifen had a mean increase in both lumbar spine and total hip BMD compared to baseline.</p>
<p>Because ARIMIDEX lowers circulating estrogen levels it may cause a reduction in bone mineral density.  </p>
<p>A post-marketing trial assessed the combined effects of ARIMIDEX and the bisphosphonate risedronate on changes from baseline in BMD and markers of bone resorption and formation in postmenopausal women with hormone receptor-positive early breast cancer. All patients received calcium and vitamin D supplementation. At 12 months, small reductions in lumbar spine bone mineral density were noted in patients not receiving bisphosphonates. Bisphosphonate treatment preserved bone density in most patients at risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>. </p>
<p>   Postmenopausal women with early breast cancer scheduled to be treated with ARIMIDEX should have their bone status managed according to treatment guidelines already available for postmenopausal women at similar risk of fragility <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></p>
<p>During the ATAC trial, more patients receiving ARIMIDEX were reported to have an elevated serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> compared to patients receiving tamoxifen (9% versus 3.5%, respectively).</p>
<p>A post-marketing trial also evaluated any potential effects of ARIMIDEX on lipid profile. In the primary analysis population for lipids (ARIMIDEX alone), there was no clinically significant change in LDL-C from baseline to 12 months and HDL-C from baseline to 12 months.</p>
<p>In secondary population for lipids (ARIMIDEX+risedronate), there also was no clinically significant change in LDL-C and HDL-C from baseline to 12 months. </p>
<p> In both populations for lipids, there was no clinically significant difference in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (TC) or serum triglycerides (TG) at 12 months compared with baseline.  </p>
<p>In this trial, treatment for 12 months with ARIMIDEX alone had a neutral effect on lipid profile. Combination treatment with ARIMIDEX and risedronate also had a neutral effect on lipid profile. </p>
<p> The trial provides evidence that postmenopausal women with early breast cancer scheduled to be treated with ARIMIDEX should be managed using the current National <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> Education Program guidelines for cardiovascular risk-based management of individual patients with LDL elevations.</p>
<p><span class="Italics">Other Adverse Reactions</span></p>
<p>Patients receiving ARIMIDEX had an increase in <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorders</span> (including <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>) compared with patients receiving tamoxifen. Patients receiving ARIMIDEX had an increase in the incidence of all <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>  (specifically  <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of spine, hip and wrist) [315 (10%)] compared with patients receiving tamoxifen [209 (7%)]. </p>
<p>Patients receiving ARIMIDEX had a higher incidence of <span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span> [78 (2.5%)] compared with patients receiving tamoxifen [22 (0.7%)].</p>
<p><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> occurred more frequently in the tamoxifen-treated patients versus the ARIMIDEX-treated patients 317 (10%) versus 167 (5%), respectively.</p>
<p>Patients receiving ARIMIDEX had a lower incidence of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, endometrial cancer, venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> and ischemic cerebrovascular events compared with patients receiving tamoxifen.</p>
<p><span class="Italics">10-year median follow-up Safety Results from the ATAC Trial </span></p>
<p>â€¢ Results are consistent with the previous analyses. </p>
<p>â€¢ Serious adverse reactions were similar between ARIMIDEX (50%) and tamoxifen (51%).</p>
<p>â€¢ Cardiovascular events were consistent with the known safety profiles of ARIMIDEX and tamoxifen. </p>
<p>â€¢ The cumulative incidences of all first <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> (both serious and non-serious, occurring either during or after treatment) was higher in the ARIMIDEX group (15%) compared to the tamoxifen group (11%). This increased first <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> rate during treatment did not continue in the post-treatment follow-up period. </p>
<p>â€¢ The cumulative incidence of new primary cancers was similar in the ARIMIDEX group (13.7%) compared to the tamoxifen group (13.9%). Consistent with the previous analyses, endometrial cancer was higher in the tamoxifen group (0.8%) compared to the ARIMIDEX group (0.2%).</p>
<p>â€¢ The overall number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (during or off-trial treatment) was similar between the treatment groups. There were more <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> related to breast cancer in the tamoxifen than in the ARIMIDEX treatment group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3>      First-Line Therapy</h3>
<p class="First">Adverse reactions occurring with an incidence of at least 5% in either treatment group of trials 0030 and 0027 during or within 2 weeks of the end of treatment are shown in TableÂ 3.</p>
<a name="i473a5543-7425-4082-8cae-0feb1207e17b"></a><table frame="hsides">
<caption><span>Table 3 â€“ Adverse Reactions Occurring with an Incidence of at Least 5% in Trials 0030 and 0027</span></caption>
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead>
<tr class="First">
<td align="left" valign="top">
<p class="First"><span class="Bold">Body system</span></p>
<p><span class="Bold">	Adverse Reaction
                                             </span></p>
</td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number (%) of subjects</span></p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">(N=506)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">(N=511)</span></p>
</td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="Bold">Whole body</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td align="left" valign="top"><p class="First">Â 83 (16)</p></td>
<td align="left" valign="top"><p class="First">81 (16)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td align="left" valign="top"><p class="First">70 (14)	</p></td>
<td align="left" valign="top"><p class="First">73 (14)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></p></td>
<td align="left" valign="top"><p class="First">60 (12)</p></td>
<td align="left" valign="top"><p class="First">68 (13)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="left" valign="top"><p class="First">47Â Â Â (9)</p></td>
<td align="left" valign="top"><p class="First">40Â Â Â (8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td align="left" valign="top"><p class="First">40Â Â Â (8)</p></td>
<td align="left" valign="top"><p class="First">38Â Â Â (7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
<td align="left" valign="top"><p class="First">37Â Â Â (7)</p></td>
<td align="left" valign="top"><p class="First">37Â Â Â (7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span></p></td>
<td align="left" valign="top"><p class="First">35Â Â Â (7)</p></td>
<td align="left" valign="top"><p class="First">30Â Â Â (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic pain</span></p></td>
<td align="left" valign="top"><p class="First">23Â Â Â (5)</p></td>
<td align="left" valign="top"><p class="First">30Â Â Â (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Cardiovascular</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Vasodilation</p></td>
<td align="left" valign="top"><p class="First">128Â (25)</p></td>
<td align="left" valign="top"><p class="First">106Â (21)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td align="left" valign="top"><p class="First">25Â Â Â (5)</p></td>
<td align="left" valign="top"><p class="First">36Â Â Â (7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Digestive</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="left" valign="top"><p class="First">94Â (19)</p></td>
<td align="left" valign="top"><p class="First">106Â (21)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td align="left" valign="top"><p class="First">47Â Â Â (9)</p></td>
<td align="left" valign="top"><p class="First">66Â (13)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="left" valign="top"><p class="First">40Â Â Â (8)</p></td>
<td align="left" valign="top"><p class="First">33Â Â Â (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="left" valign="top"><p class="First">38Â Â Â (8)</p></td>
<td align="left" valign="top"><p class="First">36Â Â Â (7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td align="left" valign="top"><p class="First">26Â Â Â (5)</p></td>
<td align="left" valign="top"><p class="First">46Â Â Â (9)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Metabolic and Nutritional</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></p></td>
<td align="left" valign="top"><p class="First">51 (10)</p></td>
<td align="left" valign="top"><p class="First">41Â Â Â (8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Muscoloskeletal</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></p></td>
<td align="left" valign="top"><p class="First">54Â Â (11)</p></td>
<td align="left" valign="top"><p class="First">52Â (10)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Nervous</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="left" valign="top"><p class="First">30Â Â Â (6)</p></td>
<td align="left" valign="top"><p class="First">22Â Â Â (4)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td align="left" valign="top"><p class="First">30Â Â Â (6)</p></td>
<td align="left" valign="top"><p class="First">38Â Â Â (7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td align="left" valign="top"><p class="First">23Â Â Â (5)</p></td>
<td align="left" valign="top"><p class="First">32Â Â Â (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span></p></td>
<td align="left" valign="top"><p class="First">16Â Â Â (3)</p></td>
<td align="left" valign="top"><p class="First">26Â Â Â (5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Respiratory</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span></p></td>
<td align="left" valign="top"><p class="First">55Â Â (11)</p></td>
<td align="left" valign="top"><p class="First">52Â (10)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td align="left" valign="top"><p class="First">51Â Â (10)</p></td>
<td align="left" valign="top"><p class="First">47Â Â Â (9)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td align="left" valign="top"><p class="First">49Â Â (10)</p></td>
<td align="left" valign="top"><p class="First">68Â (13)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Skin and appendages</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td align="left" valign="top"><p class="First">38Â Â Â (8)</p></td>
<td align="left" valign="top"><p class="First">34Â Â Â (8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Urogenital</span></p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">Leukorrhea</span></p></td>
<td align="left" valign="top"><p class="First">9Â Â (2)	</p></td>
<td align="left" valign="top"><p class="First">31Â Â Â (6)</p></td>
</tr>
</tbody>
</table>
<p>Less frequent adverse experiences reported in patients receiving ARIMIDEX 1 mg in either Trial 0030 or TrialÂ 0027 were similar to those reported for second-line therapy.</p>
<p>Based on results from second-line therapy and the established safety profile of tamoxifen, the incidences of 9Â pre-specified adverse event categories potentially causally related to one or both of the therapies because of their pharmacology were statistically analyzed.  No significant differences were seen between treatment groups.</p>
<a name="i4b206e17-6318-4d5d-893a-86cc26b96e47"></a><table frame="hsides">
<caption><span>Table 4 â€“ Number of Patients with Pre-specified Adverse Reactions in Trials 0030 and 0027</span></caption>
<colgroup>
<col>
<col>
<col>
</colgroup>
<thead>
<tr class="First">
<td align="left" valign="top"></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number (n) and Percentage of Patients</span></p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First"><span class="Bold">Adverse Reaction
                                             </span></p></td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N=506)</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">NOLVADEX</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N=511)</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Includes <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4187790" conceptname="Thrombosis of retinal vein">retinal vein thrombosis</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td align="left" valign="top"><p class="First">23Â Â (5)</p></td>
<td align="left" valign="top"><p class="First">32Â Â (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4140899" conceptname="Tumor flare">Tumor Flare</span></p></td>
<td align="left" valign="top"><p class="First">15Â Â (3)</p></td>
<td align="left" valign="top"><p class="First">18Â Â (4)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Thromboembolic Disease<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td align="left" valign="top"><p class="First">18Â Â (4)</p></td>
<td align="left" valign="top"><p class="First">33Â Â (6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Venous<a href="#footnote-2" class="Sup">*</a></p></td>
<td align="left" valign="top"><p class="First">5</p></td>
<td align="left" valign="top"><p class="First">15</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Coronary and Cerebral
                                          </p></td>
<td align="left" valign="top"><p class="First">13</p></td>
<td align="left" valign="top"><p class="First">19</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disturbance</span></p></td>
<td align="left" valign="top"><p class="First">170Â (34)</p></td>
<td align="left" valign="top"><p class="First">196Â (38)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span></p></td>
<td align="left" valign="top"><p class="First">134Â (26)</p></td>
<td align="left" valign="top"><p class="First">118Â (23)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">Vaginal Dryness</span></p></td>
<td align="left" valign="top"><p class="First">9Â Â Â Â (2)</p></td>
<td align="left" valign="top"><p class="First">3Â Â Â Â Â (1)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></p></td>
<td align="left" valign="top"><p class="First">6Â Â Â Â Â (1)</p></td>
<td align="left" valign="top"><p class="First">15Â Â Â (3)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></p></td>
<td align="left" valign="top"><p class="First">5Â Â Â Â Â (1)</p></td>
<td align="left" valign="top"><p class="First">11Â Â Â (2)</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></p></td>
<td align="left" valign="top"><p class="First">11 (2)</p></td>
<td align="left" valign="top"><p class="First">8 (2)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<h3>      Second-Line Therapy</h3>
<p class="First">ARIMIDEX was tolerated in two controlled clinical trials (i.e., Trials 0004 and 0005), with less than 3.3% of the ARIMIDEX-treated patients and 4.0% of the megestrol acetate-treated patients withdrawing due to an adverse reaction.</p>
<p>The principal adverse reaction more common with ARIMIDEX than megestrol acetate was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Adverse reactions reported in greater than 5% of the patients in any of the treatment groups in these two controlled clinical trials, regardless of causality, are presented below:</p>
<a name="i1d441b6c-7977-40bc-8ffd-498ce0deb08d"></a><table frame="hsides">
<caption><span>Table 5 â€“ Number (N) and Percentage of Patients with Adverse Reactions in Trials 0004 and 0005</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<thead>
<tr class="First">
<td align="left" rowspan="4" valign="top"><p class="First"><span class="Bold">Adverse Reaction
                                             </span></p></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">ARIMIDEX</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">ARIMIDEX</span></p></td>
<td align="left" colspan="2" valign="top">
<p class="First"><span class="Bold">Megestrol</span></p>
<p><span class="Bold"> Acetate</span></p>
</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">1 mg</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">10 mg</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">160 mg</span></p></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">(N=262)</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">(N=246)</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">(N=253)</span></p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">%</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">%</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">%</span></p></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td align="left" valign="top"><p class="First">42</p></td>
<td align="left" valign="top"><p class="First">(16)</p></td>
<td align="left" valign="top"><p class="First">33</p></td>
<td align="left" valign="top"><p class="First">(13)</p></td>
<td align="left" valign="top"><p class="First">47</p></td>
<td align="left" valign="top"><p class="First">(19)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td align="left" valign="top"><p class="First">41</p></td>
<td align="left" valign="top"><p class="First">(16)</p></td>
<td align="left" valign="top"><p class="First">48</p></td>
<td align="left" valign="top"><p class="First">(20)</p></td>
<td align="left" valign="top"><p class="First">28</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="left" valign="top"><p class="First">34</p></td>
<td align="left" valign="top"><p class="First">(13)</p></td>
<td align="left" valign="top"><p class="First">44</p></td>
<td align="left" valign="top"><p class="First">(18)</p></td>
<td align="left" valign="top"><p class="First">24</p></td>
<td align="left" valign="top"><p class="First">(9)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flashes</span></p></td>
<td align="left" valign="top"><p class="First">32</p></td>
<td align="left" valign="top"><p class="First">(12)</p></td>
<td align="left" valign="top"><p class="First">29</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
<td align="left" valign="top"><p class="First">21</p></td>
<td align="left" valign="top"><p class="First">(8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td align="left" valign="top"><p class="First">28</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
<td align="left" valign="top"><p class="First">38</p></td>
<td align="left" valign="top"><p class="First">(15)</p></td>
<td align="left" valign="top"><p class="First">29</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td align="left" valign="top"><p class="First">28</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
<td align="left" valign="top"><p class="First">26</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
<td align="left" valign="top"><p class="First">19</p></td>
<td align="left" valign="top"><p class="First">(8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td align="left" valign="top"><p class="First">24</p></td>
<td align="left" valign="top"><p class="First">(9)</p></td>
<td align="left" valign="top"><p class="First">27</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
<td align="left" valign="top"><p class="First">53</p></td>
<td align="left" valign="top"><p class="First">(21)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td align="left" valign="top"><p class="First">24</p></td>
<td align="left" valign="top"><p class="First">(9)</p></td>
<td align="left" valign="top"><p class="First">26</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
<td align="left" valign="top"><p class="First">16</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough Increased</span></p></td>
<td align="left" valign="top"><p class="First">22</p></td>
<td align="left" valign="top"><p class="First">(8)</p></td>
<td align="left" valign="top"><p class="First">18</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
<td align="left" valign="top"><p class="First">19</p></td>
<td align="left" valign="top"><p class="First">(8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td align="left" valign="top"><p class="First">22</p></td>
<td align="left" valign="top"><p class="First">(8)</p></td>
<td align="left" valign="top"><p class="First">18</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
<td align="left" valign="top"><p class="First">7</p></td>
<td align="left" valign="top"><p class="First">(3)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td align="left" valign="top"><p class="First">18</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
<td align="left" valign="top"><p class="First">18</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
<td align="left" valign="top"><p class="First">21</p></td>
<td align="left" valign="top"><p class="First">(8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td align="left" valign="top"><p class="First">18</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
<td align="left" valign="top"><p class="First">14</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
<td align="left" valign="top"><p class="First">18</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td align="left" valign="top"><p class="First">18</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
<td align="left" valign="top"><p class="First">19</p></td>
<td align="left" valign="top"><p class="First">(8)</p></td>
<td align="left" valign="top"><p class="First">11</p></td>
<td align="left" valign="top"><p class="First">(4)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone Pain</span></p></td>
<td align="left" valign="top"><p class="First">17</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
<td align="left" valign="top"><p class="First">26</p></td>
<td align="left" valign="top"><p class="First">(12)</p></td>
<td align="left" valign="top"><p class="First">19</p></td>
<td align="left" valign="top"><p class="First">(8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td align="left" valign="top"><p class="First">16</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
<td align="left" valign="top"><p class="First">23</p></td>
<td align="left" valign="top"><p class="First">(9)</p></td>
<td align="left" valign="top"><p class="First">15</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td align="left" valign="top"><p class="First">16</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
<td align="left" valign="top"><p class="First">12</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
<td align="left" valign="top"><p class="First">15</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td align="left" valign="top"><p class="First">15</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
<td align="left" valign="top"><p class="First">15</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
<td align="left" valign="top"><p class="First">19</p></td>
<td align="left" valign="top"><p class="First">(8)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></p></td>
<td align="left" valign="top"><p class="First">15</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
<td align="left" valign="top"><p class="First">11</p></td>
<td align="left" valign="top"><p class="First">(4)</p></td>
<td align="left" valign="top"><p class="First">13</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span></p></td>
<td align="left" valign="top"><p class="First">14</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
<td align="left" valign="top"><p class="First">21</p></td>
<td align="left" valign="top"><p class="First">(9)</p></td>
<td align="left" valign="top"><p class="First">28</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic Pain</span></p></td>
<td align="left" valign="top"><p class="First">14</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
<td align="left" valign="top"><p class="First">17</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
<td align="left" valign="top"><p class="First">13</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td align="left" valign="top"><p class="First">14</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
<td align="left" valign="top"><p class="First">6</p></td>
<td align="left" valign="top"><p class="First">(2)</p></td>
<td align="left" valign="top"><p class="First">5</p></td>
<td align="left" valign="top"><p class="First">(2)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td align="left" valign="top"><p class="First">13</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
<td align="left" valign="top"><p class="First">18</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
<td align="left" valign="top"><p class="First">13</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td align="left" valign="top"><p class="First">12</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
<td align="left" valign="top"><p class="First">15</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
<td align="left" valign="top"><p class="First">9</p></td>
<td align="left" valign="top"><p class="First">(4)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Hemorrhage</span></p></td>
<td align="left" valign="top"><p class="First">6</p></td>
<td align="left" valign="top"><p class="First">(2)</p></td>
<td align="left" valign="top"><p class="First">4</p></td>
<td align="left" valign="top"><p class="First">(2)</p></td>
<td align="left" valign="top"><p class="First">13</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></p></td>
<td align="left" valign="top"><p class="First">4</p></td>
<td align="left" valign="top"><p class="First">(2)</p></td>
<td align="left" valign="top"><p class="First">9</p></td>
<td align="left" valign="top"><p class="First">(4)</p></td>
<td align="left" valign="top"><p class="First">30</p></td>
<td align="left" valign="top"><p class="First">(12)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></p></td>
<td align="left" valign="top"><p class="First">4</p></td>
<td align="left" valign="top"><p class="First">(2)</p></td>
<td align="left" valign="top"><p class="First">3</p></td>
<td align="left" valign="top"><p class="First">(1)</p></td>
<td align="left" valign="top"><p class="First">16</p></td>
<td align="left" valign="top"><p class="First">(6)</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased Appetite</span></p></td>
<td align="left" valign="top"><p class="First">0</p></td>
<td align="left" valign="top"><p class="First">(0)</p></td>
<td align="left" valign="top"><p class="First">1</p></td>
<td align="left" valign="top"><p class="First">(0)</p></td>
<td align="left" valign="top"><p class="First">13</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
</tr>
</tbody>
</table>
<p>Other less frequent (2% to 5%) adverse reactions reported in patients receiving ARIMIDEX 1 mg in either Trial 0004 or Trial 0005 are listed below.  These adverse experiences are listed by body system and are in order of decreasing frequency within each body system regardless of assessed causality.</p>
<p><span class="Bold">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>; <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>; <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>; <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></p>
<p><span class="Bold">Cardiovascular: </span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>; <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span></p>
<p><span class="Bold">Hepatic:</span> <span class="product-label-link" type="condition" conceptid="4171925" conceptname="Gamma-glutamyl transferase raised">Gamma GT increased</span>; <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased; SGPT increased</p>
<p><span class="Bold">Hematologic:</span>  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span></p>
<p><span class="Bold">Metabolic and Nutritional:</span> Alkaline phosphatase increased; <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></p>
<p>Mean serum total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels increased by 0.5Â mmol/L among patients receiving ARIMIDEX.  Increases in LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> have been shown to contribute to these changes.</p>
<p><span class="Bold">Musculoskeletal:</span>  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>; <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">pathological fracture</span></p>
<p><span class="Bold">Nervous: </span> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>; <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>; <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></p>
<p><span class="Bold">Respiratory:</span>  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>; <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>; <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span></p>
<p><span class="Bold">Skin and Appendages:</span> Â <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair thinning</span> (<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>); <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Bold">Urogenital:</span>  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span>; <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span></p>
<p>The incidences of the following adverse reaction groups potentially causally related to one or both of the therapies because of their pharmacology, were statistically analyzed:  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, thromboembolic disease, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbance</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, and <span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">vaginal dryness</span>.  These six groups, and the adverse reactions captured in the groups, were prospectively defined.  The results are shown in the table below.</p>
<a name="i616eb312-3dcf-4d73-8a1d-e7f076ad60fe"></a><table frame="hsides">
<caption><span>Table 6 â€” Number (n) and Percentage of Patients with Pre-specified Adverse Reactions in Trials 0004 and 0005</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<thead>
<tr class="First">
<td align="left" rowspan="3" valign="top"></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">ARIMIDEX</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">ARIMIDEX</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Megestrol Acetate</span></p></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">1 mg</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">10 mg</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">160 mg</span></p></td>
</tr>
<tr>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">(N=262)</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">(N=246)</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">(N=253)</span></p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First"><span class="Bold">Adverse Reaction Group</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">(%)</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">(%)</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">n</span></p></td>
<td align="left" valign="top"><p class="First"><span class="Bold">(%)</span></p></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disturbance</span></p></td>
<td align="left" valign="top"><p class="First">77</p></td>
<td align="left" valign="top"><p class="First">(29)</p></td>
<td align="left" valign="top"><p class="First">81</p></td>
<td align="left" valign="top"><p class="First">(33)</p></td>
<td align="left" valign="top"><p class="First">54</p></td>
<td align="left" valign="top"><p class="First">(21)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span></p></td>
<td align="left" valign="top"><p class="First">33</p></td>
<td align="left" valign="top"><p class="First">(13)</p></td>
<td align="left" valign="top"><p class="First">29</p></td>
<td align="left" valign="top"><p class="First">(12)</p></td>
<td align="left" valign="top"><p class="First">35</p></td>
<td align="left" valign="top"><p class="First">(14)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td align="left" valign="top"><p class="First">19</p></td>
<td align="left" valign="top"><p class="First">(7)</p></td>
<td align="left" valign="top"><p class="First">28</p></td>
<td align="left" valign="top"><p class="First">(11)</p></td>
<td align="left" valign="top"><p class="First">35</p></td>
<td align="left" valign="top"><p class="First">(14)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Thromboembolic Disease</p></td>
<td align="left" valign="top"><p class="First">9</p></td>
<td align="left" valign="top"><p class="First">(3)</p></td>
<td align="left" valign="top"><p class="First">4</p></td>
<td align="left" valign="top"><p class="First">(2)</p></td>
<td align="left" valign="top"><p class="First">12</p></td>
<td align="left" valign="top"><p class="First">(5)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4135950" conceptname="Vaginal dryness">Vaginal Dryness</span></p></td>
<td align="left" valign="top"><p class="First">5</p></td>
<td align="left" valign="top"><p class="First">(2)</p></td>
<td align="left" valign="top"><p class="First">3</p></td>
<td align="left" valign="top"><p class="First">(1)</p></td>
<td align="left" valign="top"><p class="First">2</p></td>
<td align="left" valign="top"><p class="First">(1)</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></p></td>
<td align="left" valign="top"><p class="First">4</p></td>
<td align="left" valign="top"><p class="First">(2)</p></td>
<td align="left" valign="top"><p class="First">10</p></td>
<td align="left" valign="top"><p class="First">(4)</p></td>
<td align="left" valign="top"><p class="First">30</p></td>
<td align="left" valign="top"><p class="First">(12)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1231182451435"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">Hepatobiliary events including increases in alkaline phosphatase, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> have been reported (<span class="Underline">&gt;</span>1% and &lt;10%)  and gamma-GT, bilirubin and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been reported (<span class="Underline">&gt;</span> 0.1% and &lt;1%) in patients receiving ARIMIDEX.</p>
<p>ARIMIDEX may also be associated with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> including cases of mucocutaneous disorders such as <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. </p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported in patients receiving ARIMIDEX [see <span class="Italics">Contraindications (<a href="#rowellsl1231180831679">4.2</a>)</span>].</p>
<p><span class="product-label-link" type="condition" conceptid="77965" conceptname="Acquired trigger finger">Trigger finger</span> has been reported (&gt;0.1% and &lt;1%) in patients receiving ARIMIDEX.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>7   DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186587126555"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Tamoxifen</h2>
<p class="First">Co-administration of anastrozole and tamoxifen in breast cancer patients reduced anastrozole plasma concentration by 27%. However, the co-administration of anastrozole and tamoxifen did not affect the pharmacokinetics of tamoxifen or N-desmethyltamoxifen. At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation. This treatment arm was discontinued from the trial [see <span class="Italics">Clinical Studies <a href="#rowellsl1186587182242">(14.1)</a></span>]. Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1231180890007"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Estrogen</h2>
<p class="First">Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacological action.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>7.3 Warfarin</h2>
<p class="First">In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C<span class="Sub">max</span> and AUC) and anticoagulant activity (as measured by <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span>, and <span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">thrombin time</span>) of both R- and S-warfarin. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>7.4 Cytochrome P450</h2>
<p class="First">Based on <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> results, it is unlikely that co-administration of ARIMIDEX 1 mg will affect other drugs as a result inhibition of cytochrome P450 [see <span class="Italics">Clinical Pharmacology (<a href="#rowellsl1231183444178">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="rowellsl1231180632025"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">PREGNANCY CATEGORY X [see <span class="Italics">Contraindications (<a href="#rowellsl1186581032719">4.1</a></span>)]</p>
<p>ARIMIDEX may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer.  ARIMIDEX is contraindicated in women who are or may become pregnant. In animal studies, anastrozole caused pregnancy failure, increased pregnancy loss, and signs of delayed fetal development.  There are no studies of ARIMIDEX use in pregnant women. If ARIMIDEX is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus and potential risk for pregnancy loss.</p>
<p>In animal reproduction studies, pregnant rats and rabbits received anastrozole during organogenesis at doses equal to or greater than 1 (rats) and 1/3 (rabbits) the recommended human dose on a mg/m<span class="Sup">2</span> basis. In both species, anastrozole crossed the placenta, and there was increased pregnancy loss (increased pre- and/or post-implantation loss, increased resorption, and decreased numbers of live fetuses).  In rats, these effects were dose related, and placental weights were significantly increased. Fetotoxicity, including delayed fetal development (i.e., incomplete ossification and depressed fetal body weights), occurred in rats at anastrozole doses that produced peak plasma levels 19 times higher than serum levels in humans at the therapeutic dose (AUC<span class="Sub">0-24hr</span> 9 times higher). In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 16 times the recommended human dose on a mg/m<span class="Sup">2 </span>basis [see <span class="Italics">Animal Toxicology and/or Pharmacology (<a href="#rowellsl1231183480709">13.2</a>)</span>].  </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if anastrozole is excreted in human milk.  Because many drugs are excreted in human milk and because of the tumorigenicity shown for anastrozole in animal studies, or the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="rowellsl1231180931523"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Clinical studies in pediatric patients included a placebo-controlled trial in pubertal boys of adolescent age with <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> and a single-arm trial in girls with McCune-Albright Syndrome and progressive <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>.  The efficacy of ARIMIDEX in the treatment of pubertal <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> in adolescent boys and in the treatment of <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span> in girls with McCune-Albright Syndrome has not been demonstrated.</p>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> Study </p>
<p>	A randomized, double-blind, placebo-controlled, multi-center study enrolled 80 boys with pubertal <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> aged 11 to 18 years.  Patients were randomized to a daily regimen of either ARIMIDEX 1 mg or placebo.  After 6 months of treatment there was no statistically significant difference in the percentage of patients who experienced a â‰¥50% reduction in <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> (primary efficacy analysis).  Secondary efficacy analyses (absolute change in breast volume, the percentage of patients who had any reduction in the calculated volume of <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> resolution) were consistent with the primary efficacy analysis.  Serum estradiol concentrations at Month 6 of treatment were reduced by 15.4% in the ARIMIDEX group and  4.5% in the placebo group. </p>
<p>Adverse reactions that were assessed as treatment-related by the investigators occurred in 16.3% of the ARIMIDEX-treated patients and 8.1% of the placebo-treated patients with the most frequent being <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> (7% ARIMIDEX and 2.7% placebo) and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (7% ARIMIDEX and 0% placebo); all other adverse reactions showed small differences between treatment groups. One patient treated with ARIMIDEX discontinued the trial because of testicular enlargement.  The mean baseline-subtracted change  in testicular volume after 6 months of treatment was + 6.6 Â± 7.9 cm<span class="Sup">3</span> in the ARIMIDEX-treated patients and + 5.2 Â± 8.0 cm<span class="Sup">3</span> in the placebo group.</p>
<p>McCune-Albright Syndrome Study</p>
<p> A multi-center, single-arm, open-label study was conducted in 28 girls with McCune-Albright Syndrome and progressive <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span> aged 2 to &lt;10 years.  All patients received a 1 mg daily dose of ARIMIDEX.  The trial duration was 12 months. Patients were enrolled on the basis of a diagnosis of typical (27/28) or atypical (1/27) McCune-Albright Syndrome, <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>, history of <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, and/or advanced bone age.  Patientsâ€™ baseline characteristics included the following: a mean chronological age of 5.9 Â± 2.0 years, a mean bone age of 8.6 Â± 2.6 years, a mean growth rate of 7.9 Â± 2.9 cm/year and a mean Tanner stage for breast of 2.7 Â± 0.81.  Compared to pre-treatment data there were no on-treatment statistically significant reductions in the frequency of <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> days, or in the rate of increase of bone age (defined as a ratio between the change in bone age over the change of chronological age).  There were no clinically significant changes in Tanner staging, mean ovarian volume, mean uterine volume and mean predicted adult height.  A small but statistically significant reduction of growth rate from 7.9 Â± 2.9 cm/year to 6.5 Â± 2.8 cm/year was observed but the absence of a control group precludes attribution of this effect to treatment or to other confounding factors such as variations in endogenous estrogen levels commonly seen in McCune-Albright Syndrome patients.</p>
<p>Five patients (18%) experienced adverse reactions that were considered possibly related to ARIMIDEX. These were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in an extremity, increased alanine transaminase and aspartate transaminase, and <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>. </p>
<p>Pharmacokinetics in Pediatric Patients</p>
<p> Following 1 mg once daily multiple administration in pediatric patients, the mean time to reach the maximum anastrozole concentration was 1 hr. The mean (range) disposition parameters of anastrozole in pediatric patients were described by a CL/F of 1.54 L/h (0.77-4.53 L/h) and V/F of 98.4 L (50.7-330.0 L). The terminal elimination half-life was 46.8 h, which was similar to that observed in postmenopausal women treated with anastrozole for breast cancer. Based on a population pharmacokinetic analysis, the pharmacokinetics of anastrozole was similar in boys with pubertal <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> and girls with McCune-Albright Syndrome.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In studies 0030 and 0027, about 50% of patients were 65 or older. Patients â‰¥ 65 years of age had moderately better tumor response and time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> than patients &lt; 65 years of age regardless of randomized treatment.  In studies 0004 and 0005, 50% of patients were 65 or older.  Response rates and time to progression were similar for the over 65 and younger patients.</p>
<p>In the ATAC study, 45% of patients were 65 years of age or older.  The efficacy of ARIMIDEX compared to tamoxifen in patients who were 65 years or older (N=1413 for ARIMIDEX and N=1410 for tamoxifen, the hazard ratio for disease-free survival was 0.93 [95% CI: 0.80, 1.08]) was less than efficacy observed in patients who were less than 65 years of age (N=1712 for ARIMIDEX and N=1706 for tamoxifen, the hazard ratio for disease-free survival was 0.79 [95% CI: 0.67, 0.94]). </p>
<p>The pharmacokinetics of anastrozole are not affected by age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186580997361"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"> Since only about 10% of anastrozole is excreted unchanged in the urine, the <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> does not influence the total body clearance. Dosage adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not necessary <span class="Italics">[see Dosage and Administration (<a href="#rowellsl1231183533193">2.1</a>) and Clinical Pharmacology (<a href="#rowellsl1231183563896">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186580971002"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The plasma anastrozole concentrations in the subjects with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> were within the range of concentrations seen in normal subjects across all clinical trials. Therefore, dosage adjustment is also not necessary in patients with stable <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>. ARIMIDEX has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [see <span class="Italics">Dosage and Administration (<a href="#rowellsl1186587366238">2.2</a>) and Clinical Pharmacology (<a href="#rowellsl1231183617474">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">Clinical trials have been conducted with ARIMIDEX, up to 60 mg in a single dose given to healthy male volunteers and up to 10 mg daily given to postmenopausal women with advanced breast cancer; these dosages were tolerated.  A single dose of ARIMIDEX that results in life-threatening symptoms has not been established. There is no specific antidote to overdosage and treatment must be symptomatic.  In the management of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, consider that multiple agents may have been taken.  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> may be induced if the patient is alert.  Dialysis may be helpful because ARIMIDEX is not highly protein bound.  General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">ARIMIDEX (anastrozole) tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor.  It is chemically described as 1,3-Benzenediacetonitrile, a, a, a', a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl).  Its molecular formula is C<span class="Sub">17</span>H<span class="Sub">19</span>N<span class="Sub">5</span> and its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure for anastrozole" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a&amp;name=arimidex-chem.jpg"></div>
<p>Anastrozole is an off-white powder with a molecular weight of 293.4.   Anastrozole has moderate aqueous solubility (0.5 mg/mL at 25Â°C); solubility is independent of pH in the physiological range.   Anastrozole is freely soluble in methanol, acetone, ethanol, and tetrahydrofuran, and very soluble in acetonitrile.</p>
<p>Each tablet contains as inactive ingredients:  lactose, magnesium stearate, hydroxypropylmethylcellulose, polyethylene glycol, povidone, sodium starch glycolate, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The growth of many cancers of the breast is stimulated or maintained by estrogens.</span></p>
<p>In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.</p>
<p style="border-left:1px solid;"><span class="XmChange">Anastrozole is a selective non-steroidal aromatase inhibitor.  It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.</span></p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="rowellsl1186581875141"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<h3>Effect on Estradiol</h3>
<p class="First">Mean serum concentrations of estradiol were evaluated in multiple daily dosing trials with 0.5, 1, 3, 5, and 10 mg of ARIMIDEX in postmenopausal women with advanced breast cancer.  Clinically significant suppression of serum estradiol was seen with all doses.  Doses of 1 mg and higher resulted in suppression of mean serum concentrations of estradiol to the lower limit of detection (3.7 pmol/L). The recommended daily dose, ARIMIDEX 1 mg, reduced estradiol by approximately 70% within 24 hours and by approximately 80% after 14 days of daily dosing. Suppression of serum estradiol was maintained for up to 6 days after cessation of daily dosing with ARIMIDEX 1 mg.</p>
<p>The effect of ARIMIDEX in premenopausal women with early or advanced breast cancer has not been studied. Because aromatization of adrenal <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> is not a significant source of estradiol in premenopausal women, ARIMIDEX would not be expected to lower estradiol levels in premenopausal women.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<h3>Effect on Corticosteroids</h3>
<p class="First">In multiple daily dosing trials with 3, 5, and 10 mg, the selectivity of anastrozole was assessed by examining effects on corticosteroid synthesis. For all doses, anastrozole did not affect cortisol or aldosterone secretion at baseline or in response to ACTH.  No glucocorticoid or mineralocorticoid replacement therapy is necessary with anastrozole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<h3>Other Endocrine Effects</h3>
<p class="First">In multiple daily dosing trials with 5 and 10 mg, thyroid stimulating hormone (TSH) was measured; there was no increase in TSH during the administration of ARIMIDEX.  ARIMIDEX does not possess direct progestogenic, androgenic, or estrogenic activity in animals, but does perturb the circulating levels of progesterone, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span>, and estrogens.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="rowellsl1231183444178"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<h3><span class="Italics">Absorption</span></h3>
<p class="First">Inhibition of aromatase activity is primarily due to anastrozole, the parent drug. Absorption of anastrozole is rapid and maximum plasma concentrations typically occur within 2 hours of dosing under fasted conditions. Studies with radiolabeled drug have demonstrated that orally administered anastrozole is well absorbed into the systemic circulation. Food reduces the rate but not the overall extent of anastrozole absorption. The mean C<span class="Sub">max</span> of anastrozole decreased by 16% and the median T<span class="Sub">max</span> was delayed from 2 to 5 hours when anastrozole was administered 30 minutes after food. The pharmacokinetics of anastrozole are linear over the dose range of 1 to 20 mg, and do not change with repeated dosing.  The pharmacokinetics of anastrozole were similar in patients and healthy volunteers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<h3><span class="Italics">Distribution</span></h3>
<p class="First">Steady-state plasma levels are approximately 3- to 4-fold higher than levels observed after a single dose of ARIMIDEX.  Plasma concentrations approach steady-state levels at about 7 days of once daily dosing. Anastrozole is 40% bound to plasma proteins in the therapeutic range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<h3><span class="Italics">Metabolism</span></h3>
<p class="First">Metabolism of anastrozole occurs by N-dealkylation, hydroxylation and glucuronidation. Three metabolites of anastrozole (triazole, a glucuronide conjugate of hydroxy-anastrozole, and a glucuronide conjugate of anastrozole itself) have been identified in human plasma and urine. The major circulating metabolite of anastrozole, triazole, lacks pharmacologic activity.</p>
<p>Anastrozole inhibited reactions catalyzed by cytochrome P450 1A2, 2C8/9, and 3A4 <span class="Italics">in vitro</span> with Ki values which were approximately 30 times higher than the mean steady-state C<span class="Sub">max</span> values observed following a 1 mg daily dose. Anastrozole had no inhibitory effect on reactions catalyzed by cytochrome P450 2A6 or 2D6 <span class="Italics">in vitro</span>. Administration of a single 30 mg/kg or multiple 10 mg/kg doses of anastrozole to healthy subjects had no effect on the clearance of antipyrine or urinary recovery of antipyrine metabolites.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<h3><span class="Italics">Excretion</span></h3>
<p class="First">Eighty-five percent of radiolabeled anastrozole was recovered in feces and urine.  Hepatic metabolism accounts for approximately 85% of anastrozole elimination. Renal elimination accounts for approximately 10% of total clearance.  The mean elimination half-life of anastrozole is 50 hours. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<h3><span class="Italics">Effect of Gender and Age</span></h3>
<p class="First">Anastrozole pharmacokinetics have been investigated in postmenopausal female volunteers and patients with breast cancer. No age-related effects were seen over the range &lt;50 to &gt;80 years. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<h3><span class="Italics">Effect of Race</span></h3>
<p class="First">Estradiol and estrone sulfate serum levels were similar between Japanese and Caucasian postmenopausal women who received 1 mg of anastrozole daily for 16 days. Anastrozole mean steady-state minimum plasma concentrations in Caucasian and Japanese postmenopausal women were 25.7 and 30.4 ng/mL, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1231183563896"></a><a name="section-11.3.7"></a><p></p>
<h3><span class="Italics">Effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h3>
<p class="First">Anastrozole pharmacokinetics have been investigated in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Anastrozole <span class="product-label-link" type="condition" conceptid="437992" conceptname="Renal function tests abnormal">renal clearance decreased</span> proportionally with creatinine clearance and was approximately 50% lower in volunteers with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt; 30 mL/min/1.73m<span class="Sup">2</span>) compared to controls. Total clearance was only reduced 10%.  No dosage adjustment is needed for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics">Dosage and Administration (<a href="#rowellsl1231183533193">2.1)</a></span> and <span class="Italics">Use in Specific Populations (<a href="#rowellsl1186580997361">8.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1231183617474"></a><a name="section-11.3.8"></a><p></p>
<h3><span class="Italics">Effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h3>
<p class="First">Anastrozole pharmacokinetics have been investigated in subjects with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> related to <span class="product-label-link" type="condition" conceptid="433753" conceptname="Alcohol abuse">alcohol abuse</span>.  The apparent oral clearance (CL/F) of anastrozole was approximately 30% lower in subjects with stable <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> than in control subjects with normal liver function.  However, these plasma concentrations were still with the range of values observed in normal subjects.  The effect of severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> was not studied.  No dose adjustment is necessary for stable <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> [see <span class="Italics">Dosage and Administration (<a href="#rowellsl1186587366238">2.2</a>)</span> and <span class="Italics">Use in Specific Populations (<a href="#rowellsl1186580971002">8.7</a>)</span>]. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A conventional carcinogenesis study in rats at doses of 1.0Â toÂ 25Â mg/kg/day (about 10 to 243 times the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) administered by oral gavage for up to 2 years revealed an increase in the incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span> and carcinoma and uterine stromal <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> in females and <span class="product-label-link" type="condition" conceptid="4114219" conceptname="Thyroid adenoma">thyroid adenoma</span> in males at the high dose.  A dose-related increase was observed in the incidence of ovarian and uterine <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> in females.  At 25 mg/kg/day, plasma AUC<span class="Sub">0-24Â hr</span> levels in rats were 110 to 125 times higher than the level exhibited in postmenopausal volunteers at the recommended dose.  A separate carcinogenicity study in mice at oral doses of 5 to 50 mg/kg/day (about 24 to 243Â times the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) for up to 2 years produced an increase in the incidence of benign ovarian stromal, epithelial and granulosa cell tumors at all dose levels.  A dose-related increase in the incidence of ovarian <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was also observed in female mice.  These ovarian changes are considered to be rodent-specific effects of aromatase inhibition and are of questionable significance to humans.  The incidence of lymphosarcoma was increased in males and females at the high dose.  At 50 mg/kg/day, plasma AUC levels in mice were 35 to 40 times higher than the level exhibited in postmenopausal volunteers at the recommended dose.</p>
<p>ARIMIDEX has not been shown to be mutagenic in <span class="Italics">in vitro</span> tests (Ames and E. coli bacterial tests, CHO-K1 gene mutation assay) or clastogenic either <span class="Italics">in vitro</span> (chromosome aberrations in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) or <span class="Italics">in vivo</span> (micronucleus test in rats).</p>
<p>Oral administration of anastrozole to female rats (from 2Â weeks before mating to pregnancy day 7) produced significant incidence of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> and reduced numbers of viable pregnancies at 1 mg/kg/day (about 10 times the recommended human dose on a mg/m<span class="Sup">2</span> basis and 9 times higher than the AUC<span class="Sub">0-24Â hr</span> found in postmenopausal volunteers at the recommended dose).  Pre-implantation loss of ova or fetus was increased at doses equal to or greater than 0.02 mg/kg/day (about one-fifth the recommended human dose on a mg/m<span class="Sup">2</span> basis).  Recovery of fertility was observed following a 5-week non-dosing period which followed 3 weeks of dosing.  It is not known whether these effects observed in female rats are indicative of impaired fertility in humans.</p>
<p>Multiple-dose studies in rats administered anastrozole for 6Â months at doses equal to or greater than 1 mg/kg/day (which produced plasma anastrozole C<span class="Sub">ssmax</span> and AUC<span class="Sub">0-24Â hr</span> that were 19 and 9 times higher than the respective values found in postmenopausal volunteers at the recommended dose) resulted in <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span> of the ovaries and the presence of follicular <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>.  In addition, hyperplastic uteri were observed in 6-month studies in female dogs administered doses equal to or greater than 1 mg/kg/day (which produced plasma anastrozole C<span class="Sub">ssmax</span> and AUC<span class="Sub">0-24Â hr</span> that were 22 times and 16 times higher than the respective values found in postmenopausal women at the recommended dose).  It is not known whether these effects on the reproductive organs of animals are associated with impaired fertility in premenopausal women.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="rowellsl1231183480709"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Italics">Reproductive Toxicology</span></p>
<p>Anastrozole has been found to cross the placenta following oral administration of 0.1 mg/kg in rats and rabbits (about 1 and 1.9 times the recommended human dose, respectively, on a mg/m<span class="Sup">2</span> basis). Studies in both rats and rabbits at doses equal to or greater than 0.1 and 0.02 mg/kg/day, respectively (about 1 and 1/3, respectively, the recommended human dose on a mg/m<span class="Sup">2</span> basis), administered during the period of organogenesis showed that anastrozole increased pregnancy loss (increased pre- and/or post-implantation loss, increased resorption, and decreased numbers of live fetuses); effects were dose related in rats. Placental weights were significantly increased in rats at doses of 0.1 mg/kg/day or more.</p>
<p>Evidence of fetotoxicity, including delayed fetal development (i.e., incomplete ossification and depressed fetal body weights), was observed in rats administered doses of 1 mg/kg/day (which produced plasma anastrozole C<span class="Sub">ssmax</span> and AUC<span class="Sub">0-24 hr</span> that were 19 times and 9 times higher than the respective values found in postmenopausal volunteers at the recommended dose). There was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rats administered doses up to 1.0 mg/kg/day. In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 1.0 mg/kg/day (about 16 times the recommended human dose on a mg/m<span class="Sup">2</span> basis); there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in rabbits administered 0.2 mg/kg/day (about 3 times the recommended human dose on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>14   CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="rowellsl1186587182242"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adjuvant Treatment of Breast Cancer in Postmenopausal Women</h2>
<p class="First">A multicenter, double-blind trial (ATAC) randomized 9,366 postmenopausal women with operable breast cancer to adjuvant treatment with ARIMIDEX 1 mg daily, tamoxifen 20 mg daily, or a combination of the two treatments for five years or until recurrence of the disease.  </p>
<p>The primary endpoint of the trial was disease-free survival (i.e., time to occurrence of a distant or local recurrence, or contralateral breast cancer or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause).  Secondary endpoints of the trial included distant disease-free survival, the incidence of contralateral breast cancer and overall survival.  At a median follow-up of 33 months, the combination of ARIMIDEX and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor positive subpopulation. This treatment arm was discontinued from the trial. Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole [see <span class="Italics">Drug Interactions (<a href="#rowellsl1186587126555">7.1</a>)</span>].</p>
<p>Demographic and other baseline characteristics were similar among the three treatment groups (see Table <a href="#rowellsl1231183834160">7</a>).</p>
<a name="rowellsl1231183834160"></a><table frame="hsides">
<caption><span>Table 7 - Demographic and Baseline Characteristics for ATAC Trial</span></caption>
<colgroup>
<col width="97*">
<col width="97*">
<col width="88*">
<col width="112*">
</colgroup>
<thead><tr class="First Last">
<td align="left" valign="top"><p class="First"><span class="Bold">Demographic Characteristic</span></p></td>
<td align="center" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>=3125)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N<a href="#footnote-3" class="Sup">*</a>=3116)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">ARIMIDEX 1 mg</span></p>
<p><span class="Bold">plus Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N<a href="#footnote-3" class="Sup">*</a>=3125)</span></p>
</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>N=Number of patients randomized to the treatment</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First">Mean age (yrs.)</p></td>
<td align="center" valign="top"><p class="First">64.1</p></td>
<td align="center" valign="top"><p class="First">64.1</p></td>
<td align="center" valign="top"><p class="First">64.3</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Age Range (yrs.)</p></td>
<td align="center" valign="top"><p class="First">38.1 - 92.8</p></td>
<td align="center" valign="top"><p class="First">32.8 - 94.9</p></td>
<td align="center" valign="top"><p class="First">37.0 - 92.2</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Age Distribution (%)</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	&lt;45 yrs.</p></td>
<td align="center" valign="top"><p class="First">0.7</p></td>
<td align="center" valign="top"><p class="First">0.4</p></td>
<td align="center" valign="top"><p class="First">0.5</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	45-60 yrs.</p></td>
<td align="center" valign="top"><p class="First">34.6</p></td>
<td align="center" valign="top"><p class="First">35.0</p></td>
<td align="center" valign="top"><p class="First">34.5</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	&gt;60 &lt;70 yrs.</p></td>
<td align="center" valign="top"><p class="First">38.0</p></td>
<td align="center" valign="top"><p class="First">37.1</p></td>
<td align="center" valign="top"><p class="First">37.7</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	&gt;70 yrs.</p></td>
<td align="center" valign="top"><p class="First">26.7</p></td>
<td align="center" valign="top"><p class="First">27.4</p></td>
<td align="center" valign="top"><p class="First">27.3</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Mean Weight (kg)</p></td>
<td align="center" valign="top"><p class="First">70.8</p></td>
<td align="center" valign="top"><p class="First">71.1</p></td>
<td align="center" valign="top"><p class="First">71.3</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Receptor Status (%)</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Positive
                                    </p></td>
<td align="center" valign="top"><p class="First">83.5</p></td>
<td align="center" valign="top"><p class="First">83.1</p></td>
<td align="center" valign="top"><p class="First">84.0</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Negative
                                    </p></td>
<td align="center" valign="top"><p class="First">7.4</p></td>
<td align="center" valign="top"><p class="First">8.0</p></td>
<td align="center" valign="top"><p class="First">7.0</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Other
                                    </p></td>
<td align="center" valign="top"><p class="First">8.8</p></td>
<td align="center" valign="top"><p class="First">8.6</p></td>
<td align="center" valign="top"><p class="First"> 9.0</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Other Treatment (%) prior  to Randomization</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Mastectomy</p></td>
<td align="center" valign="top"><p class="First">47.8</p></td>
<td align="center" valign="top"><p class="First">47.3</p></td>
<td align="center" valign="top"><p class="First">48.1</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Breast conservation
                                    </p></td>
<td align="center" valign="top"><p class="First">52.3</p></td>
<td align="center" valign="top"><p class="First">52.8</p></td>
<td align="center" valign="top"><p class="First">51.9</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Axillary surgery</p></td>
<td align="center" valign="top"><p class="First">95.5</p></td>
<td align="center" valign="top"><p class="First">95.7</p></td>
<td align="center" valign="top"><p class="First">95.2</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Radiotherapy</p></td>
<td align="center" valign="top"><p class="First">63.3</p></td>
<td align="center" valign="top"><p class="First">62.5</p></td>
<td align="center" valign="top"><p class="First">61.9</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Chemotherapy</p></td>
<td align="center" valign="top"><p class="First">22.3</p></td>
<td align="center" valign="top"><p class="First">20.8</p></td>
<td align="center" valign="top"><p class="First">20.8</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Neoadjuvant Tamoxifen</p></td>
<td align="center" valign="top"><p class="First">1.6</p></td>
<td align="center" valign="top"><p class="First">1.6</p></td>
<td align="center" valign="top"><p class="First">1.7</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Primary Tumor Size (%)</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	T1 (â‰¤2 cm)</p></td>
<td align="center" valign="top"><p class="First">63.9</p></td>
<td align="center" valign="top"><p class="First">62.9</p></td>
<td align="center" valign="top"><p class="First">64.1</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	T2 (&gt;2 cm and â‰¤5 cm)</p></td>
<td align="center" valign="top"><p class="First">32.6</p></td>
<td align="center" valign="top"><p class="First">34.2</p></td>
<td align="center" valign="top"><p class="First">32.9</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	T3 (&gt;5 cm)</p></td>
<td align="center" valign="top"><p class="First">2.7</p></td>
<td align="center" valign="top"><p class="First">2.2</p></td>
<td align="center" valign="top"><p class="First">2.3</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Nodal Status (%)</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Node positive</p></td>
<td align="center" valign="top"><p class="First">34.9</p></td>
<td align="center" valign="top"><p class="First">33.6</p></td>
<td align="center" valign="top"><p class="First">33.5</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	1-3 (# of nodes)</p></td>
<td align="center" valign="top"><p class="First">24.4</p></td>
<td align="center" valign="top"><p class="First">24.4</p></td>
<td align="center" valign="top"><p class="First">24.3</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	4-9</p></td>
<td align="center" valign="top"><p class="First">7.5</p></td>
<td align="center" valign="top"><p class="First">6.4</p></td>
<td align="center" valign="top"><p class="First">6.8</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	&gt;9</p></td>
<td align="center" valign="top"><p class="First">2.9</p></td>
<td align="center" valign="top"><p class="First">2.7</p></td>
<td align="center" valign="top"><p class="First">2.3</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Tumor Grade (%)</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Well-differentiated</p></td>
<td align="center" valign="top"><p class="First">20.8</p></td>
<td align="center" valign="top"><p class="First">20.5</p></td>
<td align="center" valign="top"><p class="First">21.2</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Moderately differentiated</p></td>
<td align="center" valign="top"><p class="First">46.8</p></td>
<td align="center" valign="top"><p class="First">47.8</p></td>
<td align="center" valign="top"><p class="First"> 46.5</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Poorly/undifferentiated</p></td>
<td align="center" valign="top"><p class="First">23.7</p></td>
<td align="center" valign="top"><p class="First">23.3</p></td>
<td align="center" valign="top"><p class="First">23.7</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First">	Not assessed/recorded</p></td>
<td align="center" valign="top"><p class="First">8.7</p></td>
<td align="center" valign="top"><p class="First">8.4</p></td>
<td align="center" valign="top"><p class="First">8.5</p></td>
</tr>
</tbody>
</table>
<p>Patients in the two monotherapy arms of the ATAC trial were treated for a median of 60 months (5 years) and followed for a median of 68 months.  Disease-free survival in the intent-to-treat population was statistically significantly improved [Hazard Ratio (HR) = 0.87, 95% CI: 0.78, 0.97, p=0.0127] in the ARIMIDEX arm compared to the tamoxifen arm.  In the hormone receptor-positive subpopulation representing about 84% of the trial patients, disease-free survival was also statistically significantly improved (HR = 0.83, 95% CI: 0.73, 0.94, p=0.0049) in the ARIMIDEX arm compared to the tamoxifen arm.</p>
<p><span class="Bold">Figure 1 â€” Disease-Free Survival Kaplan Meier Survival Curve for all Patients Randomized to ARIMIDEX or Tamoxifen Monotherapy in the ATAC trial (Intent-to-Treat)</span></p>
<div class="Figure"><img alt="figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a&amp;name=arimidex-figureone-01.jpg"></div>
<p><span class="Bold">Figure 2 â€” Disease-free Survival for Hormone Receptor-Positive Subpopulation of Patients Randomized to ARIMIDEX or Tamoxifen Monotherapy in the ATAC Trial</span></p>
<div class="Figure"><img alt="figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a&amp;name=arimidex-figuretwo-01.jpg"></div>
<p>The survival data with 68 months follow-up is presented in Table 9.</p>
<p>In the group of patients who had previous adjuvant chemotherapy (N=698 for ARIMIDEX and N=647 for tamoxifen), the hazard ratio for disease-free survival was 0.91 (95% CI: 0.73 to 1.13) in the ARIMIDEX arm compared to the tamoxifen arm.  </p>
<p>The frequency of individual events in the intent-to-treat population and the hormone receptor-positive subpopulation are described in Table 8. </p>
<a name="i6b9d2975-d77f-4497-834a-dd088c630543"></a><table frame="hsides">
<caption><span>Table 8 - All Recurrence and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> Events
                           </span></caption>
<colgroup>
<col width="99*">
<col width="97*">
<col width="99*">
<col width="97*">
<col width="100*">
</colgroup>
<thead>
<tr class="First">
<td align="left" valign="top"></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Intent-To-Treat Population<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Hormone Receptor-Positive Subpopulation<a href="#footnote-4" class="Sup">*</a></span></p></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N<a name="footnote-reference-5" href="#footnote-5" class="Sup">â€ </a>=3125)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N<a href="#footnote-5" class="Sup">â€ </a>=3116)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N<a href="#footnote-5" class="Sup">â€ </a>=2618)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">Tamoxifen </span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N<a href="#footnote-5" class="Sup">â€ </a>=2598</span></p>
</td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
<td align="left" colspan="2" valign="top"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Patients may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> into more than one category.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">â€ </a></dt>
<dd>N=Number of patients randomized</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="Bold">Median Duration of Therapy (mo)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">60</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">60</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">60</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">60</span></p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First"><span class="Bold">Median Efficacy</span></p>
<p><span class="Bold">Follow-up (mo)</span></p>
</td>
<td align="center" valign="top"><p class="First"><span class="Bold">68</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">68</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">68</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">68</span></p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Loco-regional recurrence</span><span class="Bold"></span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">119 (3.8)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">149 (4.8)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">76 (2.9)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">101 (3.9)</span></p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Contralateral breast cancer</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">35 (1.1)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">59 (1.9)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">26 (1.0)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">54 (2.1)</span></p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Invasive</p></td>
<td align="center" valign="top"><p class="First">27 (0.9)</p></td>
<td align="center" valign="top"><p class="First">52 (1.7)</p></td>
<td align="center" valign="top"><p class="First">21 (0.8)</p></td>
<td align="center" valign="top"><p class="First">48 (1.8)</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">	Ductal carcinoma</p>
<p>	inÂ situ</p>
</td>
<td align="center" valign="top"><p class="First">8 (0.3)</p></td>
<td align="center" valign="top"><p class="First">6 (0.2)</p></td>
<td align="center" valign="top"><p class="First">5 (0.2)</p></td>
<td align="center" valign="top"><p class="First">5 (0.2)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Unknown</p></td>
<td align="center" valign="top"><p class="First">0</p></td>
<td align="center" valign="top"><p class="First">1 (&lt;0.1)</p></td>
<td align="center" valign="top"><p class="First">0</p></td>
<td align="center" valign="top"><p class="First">1 (&lt;0.1)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Distant recurrence</span><span class="Bold"></span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">324 (10.4)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">375 (12.0)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">226 (8.6)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">265 (10.2)</span></p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> from Any Cause</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">411 (13.2)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">420 (13.5)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">296 (11.3)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Bold">301 (11.6)</span></p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> breast cancer</p></td>
<td align="center" valign="top"><p class="First">218 (7.0)</p></td>
<td align="center" valign="top"><p class="First">248 (8.0)</p></td>
<td align="center" valign="top"><p class="First">138 (5.3)</p></td>
<td align="center" valign="top"><p class="First">160 (6.2)</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top">
<p class="First">	<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> other reason</p>
<p>     (including unknown)</p>
</td>
<td align="center" valign="top"><p class="First">193 (6.2)</p></td>
<td align="center" valign="top"><p class="First">172 (5.5)</p></td>
<td align="center" valign="top"><p class="First">158 (6.0)</p></td>
<td align="center" valign="top"><p class="First">141 (5.4)</p></td>
</tr>
</tbody>
</table>
<p>A summary of the study efficacy results is provided in Table 9.</p>
<a name="i9a863e5e-dd9f-48c3-85e4-26468b9dacae"></a><table frame="hsides">
<caption><span>Table 9 - ATAC Efficacy Summary
                           </span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<thead>
<tr class="First">
<td align="left" valign="top"></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Intent-To-Treat Population</span></p></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Hormone Receptor-Positive Subpopulation</span></p></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold"> 1 mg</span></p>
<p><span class="Bold">(N=3125)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N=3116)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N=2618)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N=2598)</span></p>
</td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="center" colspan="4" valign="top"><p class="First"><span class="Bold">Number of Events</span></p></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="Bold">Disease-free Survival</span></p></td>
<td align="center" valign="top"><p class="First">575 </p></td>
<td align="center" valign="top"><p class="First">651 </p></td>
<td align="center" valign="top"><p class="First">424 </p></td>
<td align="center" valign="top"><p class="First">497</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Hazard ratio</p></td>
<td align="center" colspan="2" valign="top"><p class="First">0.87</p></td>
<td align="center" colspan="2" valign="top"><p class="First">0.83</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">	2-sided </p>
<p>95% CI</p>
</td>
<td align="center" colspan="2"><p class="First">0.78 to 0.97</p></td>
<td align="center" colspan="2"><p class="First">0.73 to 0.94</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	p-value</p></td>
<td align="center" colspan="2"><p class="First">0.0127</p></td>
<td align="center" colspan="2"><p class="First">0.0049</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Distant Disease-free Survival</span></p></td>
<td align="center" valign="top"><p class="First">500 </p></td>
<td align="center" valign="top"><p class="First">530</p></td>
<td align="center" valign="top"><p class="First">370</p></td>
<td align="center" valign="top"><p class="First">394</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Hazard ratio</p></td>
<td align="center" colspan="2" rowspan="2" valign="top">
<p class="First">0.94</p>
<p>0.83 to 1.06</p>
</td>
<td align="center" colspan="2" rowspan="2" valign="top">
<p class="First">0.93</p>
<p>0.80 to 1.07</p>
</td>
</tr>
<tr><td align="left" valign="top">
<p class="First">	2-sided </p>
<p>95% CI</p>
</td></tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Overall Survival</span></p></td>
<td align="center" valign="top"><p class="First">411 </p></td>
<td align="center" valign="top"><p class="First">420</p></td>
<td align="center" valign="top"><p class="First">296</p></td>
<td align="center" valign="top"><p class="First">301</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Hazard ratio </p></td>
<td align="center" colspan="2" rowspan="2" valign="top">
<p class="First">0.97</p>
<p>0.85 to 1.12</p>
</td>
<td align="center" colspan="2" rowspan="2" valign="top">
<p class="First">0.97</p>
<p>0.83 to 1.14</p>
</td>
</tr>
<tr class="Last"><td align="left" valign="top">
<p class="First">	2-sided </p>
<p>95% CI</p>
</td></tr>
</tbody>
</table>
<p><span class="Italics">10-year median follow-up Efficacy Results from the ATAC Trial </span></p>
<p>In a subsequent analysis of the ATAC trial, patients in the two monotherapy arms were followed for a median of 120 months (10 years). Patients received study treatment for a median of 60 months (5 years) (see Table 10).</p>
<a name="i9247fd90-9f0e-4eca-8072-294c7621773a"></a><table frame="hsides">
<caption><span>Table 10 - Efficacy Summary</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
<col>
</colgroup>
<thead>
<tr class="First">
<td align="left" valign="top"></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Intent-To-Treat Population</span></p></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Hormone Receptor-Positive Subpopulation</span></p></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold"> 1 mg</span></p>
<p><span class="Bold">(N=3125)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N=3116)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N=2618)</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N=2598)</span></p>
</td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number of Events</span></p></td>
<td colspan="2"><p class="First"><span class="Bold">Number of Events</span></p></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="Bold">Disease-free Survival</span></p></td>
<td align="center" valign="top"><p class="First">953 </p></td>
<td align="center" valign="top"><p class="First">1022 </p></td>
<td align="center" valign="top"><p class="First">735</p></td>
<td align="center" valign="top"><p class="First">924</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Hazard ratio</p></td>
<td align="center" colspan="2" valign="top"><p class="First">0.91</p></td>
<td align="center" colspan="2" valign="top"><p class="First">0.86</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">	2-sided </p>
<p>95% CI</p>
</td>
<td align="center" colspan="2"><p class="First">0.83 to 0.99</p></td>
<td align="center" colspan="2"><p class="First">0.78 to 0.95</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	p-value</p></td>
<td align="center" colspan="2"><p class="First">0.0365</p></td>
<td align="center" colspan="2"><p class="First">0.0027</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First"><span class="Bold">Overall Survival</span></p></td>
<td align="center" valign="top"><p class="First">734 </p></td>
<td align="center" valign="top"><p class="First">747</p></td>
<td align="center" valign="top"><p class="First">563</p></td>
<td align="center" valign="top"><p class="First">586</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Hazard ratio </p></td>
<td align="center" colspan="2" rowspan="2" valign="top">
<p class="First">0.91</p>
<p>0.88 to 1.08</p>
</td>
<td align="center" colspan="2" rowspan="2" valign="top">
<p class="First">0.95</p>
<p>0.84 to 1.06</p>
</td>
</tr>
<tr class="Last"><td align="left" valign="top">
<p class="First">	2-sided </p>
<p>95% CI</p>
</td></tr>
</tbody>
</table>
<p></p>
<p><span class="Bold">Figure 3 - Disease-Free Survival Kaplan Meier Survival Curve for all Patients Randomized to ARIMIDEX or Tamoxifen Monotherapy in the ATAC Trial (Intent-to-Treat)<span class="Sup">(a)</span></span></p>
<div class="Figure"><img alt="figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a&amp;name=arimidex-figurethree-01.jpg"></div>
<p><span class="Sup">a</span> The proportion of patients with 120 monthsâ€™ follow-up was 29.4%. </p>
<p><span class="Bold">Figure 4 - Disease-Free Survival for Hormone Receptor-Positive Subpopulation of Patients Randomized to ARIMIDEX or Tamoxifen Monotherapy in the ATAC Trial<span class="Sup">(b)</span></span></p>
<div class="Figure"><img alt="figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a&amp;name=arimidextablenumbercorrection-figfour.jpg"></div>
<p><span class="Sup">b</span>The proportion of patients with 120 monthsâ€™ follow-up was 29.8%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2>14.2 First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer</h2>
<p class="First">Two double-blind, controlled clinical studies of similar design (0030, a North American study and 0027, a predominately European study) were conducted to assess the efficacy of ARIMIDEX compared with tamoxifen as first-line therapy for hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer in postmenopausal women. A total of 1021 patients between the ages of 30 and 92 years old were randomized to receive trial treatment.  Patients were randomized to receive 1 mg of ARIMIDEX once daily or 20 mg of tamoxifen once daily. The primary endpoints for both trials were time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span>, objective tumor response rate, and safety.</p>
<p>Demographics and other baseline characteristics, including patients who had measurable and no measurable disease, patients who were given previous adjuvant therapy, the site of <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> and ethnic origin were similar for the two treatment groups for both trials.   The following table summarizes the hormone receptor status at entry for all randomized patients in trials 0030 and 0027.</p>
<a name="i56d68c13-bdfe-4179-83a2-e9fa46d4f264"></a><table frame="hsides">
<caption><span>Table 11 â€” Demographic and Other Baseline Characteristics</span></caption>
<colgroup>
<col width="102*">
<col width="95*">
<col width="98*">
<col width="95*">
<col width="96*">
</colgroup>
<thead>
<tr class="First">
<td align="left" valign="top"></td>
<td align="center" colspan="4" valign="top"><p class="First"><span class="Bold">Number (%) of subjects</span></p></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 0030</span></p></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 0027</span></p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First"><span class="Bold">Receptor status</span></p></td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N=171)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N=182)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N=340)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N=328)</span></p>
</td>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>ER=Estrogen receptor</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">â€ </a></dt>
<dd>PgR=Progesterone receptor</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First">ER<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a> and/or PgR<a name="footnote-reference-7" href="#footnote-7" class="Sup">â€ </a></p></td>
<td align="left" valign="top"><p class="First">151 (88.3)</p></td>
<td align="left" valign="top"><p class="First">162 (89.0)</p></td>
<td align="left" valign="top"><p class="First">154 (45.3)</p></td>
<td align="left" valign="top"><p class="First">144 (43.9)</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top">
<p class="First">ER<a href="#footnote-6" class="Sup">*</a> unknown, PgR<a href="#footnote-7" class="Sup">â€ </a></p>
<p>	Unknown</p>
</td>
<td align="left" valign="top"><p class="First">19 (11.1)</p></td>
<td align="left" valign="top"><p class="First">20 (11.0)</p></td>
<td align="left" valign="top"><p class="First">185 (54.4)</p></td>
<td align="left" valign="top"><p class="First">183 (55.8)</p></td>
</tr>
</tbody>
</table>
<p>For the primary endpoints, trial 0030 showed that ARIMIDEX had a statistically significant advantage over tamoxifen (p=0.006) for time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span>; objective tumor response rates were similar for ARIMIDEX and tamoxifen. Trial 0027 showed that ARIMIDEX and tamoxifen had similar objective tumor response rates and time to <span class="product-label-link" type="condition" conceptid="4168352" conceptname="Tumor progression">tumor progression</span> (see Table <a href="#rowellsl1231186411081">12</a> and Figures <a href="#rowellsl1231186460065">5</a> and <a href="#rowellsl1231186490909">6</a>).  </p>
<p>Table 12 below summarizes the results of trial 0030 and trial 0027 for the primary efficacy endpoints.</p>
<a name="rowellsl1231186411081"></a><table frame="hsides">
<caption><span>Table 12 â€“ Efficacy Results of First-line Treatment</span></caption>
<colgroup>
<col width="109*">
<col width="94*">
<col width="92*">
<col width="94*">
<col width="94*">
</colgroup>
<thead>
<tr class="First">
<td align="left" valign="top"><p class="First"><span class="Bold">Endpoint</span></p></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 0030</span></p></td>
<td align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Trial 0027</span></p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N=171)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N=182)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">(N=340)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">Tamoxifen</span></p>
<p><span class="Bold">20 mg</span></p>
<p><span class="Bold">(N=328)</span></p>
</td>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>LCL=Lower Confidence Limit</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First">Time to progression 	(TTP)</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">	Median TTP (months)</p></td>
<td align="left" valign="top"><p class="First">11.1</p></td>
<td align="left" valign="top"><p class="First">5.6</p></td>
<td align="left" valign="top"><p class="First">8.2</p></td>
<td align="left" valign="top"><p class="First">8.3</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">Number (%) of subjects</p>
<p>	Who progressed</p>
</td>
<td align="left" valign="top"><p class="First">114 (67%)</p></td>
<td align="left" valign="top"><p class="First">138 (76%)</p></td>
<td align="left" valign="top"><p class="First">249 (73%)</p></td>
<td align="left" valign="top"><p class="First">247 (75%)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Hazard ratio (LCL<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a> )
                                    </p></td>
<td align="center" colspan="2" valign="top"><p class="First">1.42 (1.15)</p></td>
<td align="center" colspan="2" valign="top"><p class="First">1.01 (0.87)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">2-sided 95% CI
                                    </p></td>
<td align="center" colspan="2" valign="top"><p class="First">(1.11, 1.82)</p></td>
<td align="center" colspan="2" valign="top"><p class="First">(0.85, 1.20)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">p-value
                                    </p></td>
<td align="center" colspan="2" valign="top"><p class="First">0.006</p></td>
<td align="center" colspan="2" valign="top"><p class="First">0.920</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Best objective response rate</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">Number (%) of subjects</p>
<p>	With CR + PR
                                    </p>
</td>
<td align="left" valign="top"><p class="First">36 (21.1%)</p></td>
<td align="left" valign="top"><p class="First">31 (17.0%)</p></td>
<td align="left" valign="top"><p class="First">112 (32.9%)</p></td>
<td align="left" valign="top"><p class="First">107 (32.6%)</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First">Odds Ratio (LCL<a href="#footnote-8" class="Sup">*</a> )
                                    </p></td>
<td align="center" colspan="2" valign="top"><p class="First">1.30 (0.83)</p></td>
<td align="center" colspan="2" valign="top"><p class="First">1.01 (0.77)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 5 - Kaplan-Meier probability of time to disease progression for all randomized patients (intent-to-treat) in Trial 0030</span></p>
<div class="Figure"><img alt="figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a&amp;name=arimidex-figurefive.jpg"></div>
<p><span class="Bold">Figure 6 - Kaplan-Meier probability of time to progression for all randomized patients (intent-to-treat) in Trial 0027</span></p>
<div class="Figure"><img alt="figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a&amp;name=arimidex-figuresix.jpg"></div>
<p></p>
<p>Results from the secondary endpoints were supportive of the results of the primary efficacy endpoints.   There were too few <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> occurring across treatment groups of both trials to draw conclusions on overall survival differences.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<h2>14.3 Second-Line Therapy in Postmenopausal Women with Advanced Breast Cancer who had Disease Progression following Tamoxifen Therapy</h2>
<p class="First">Anastrozole was studied in two controlled clinical trials (0004, a NorthÂ American study; 0005, a predominately European study) in postmenopausal women with advanced breast cancer who had disease progression following tamoxifen therapy for either advanced or early breast cancer.  Some of the patients had also received previous cytotoxic treatment.  Most patients were ER-positive; a smaller fraction were ER-unknown or ER-negative; the ER-negative patients were eligible only if they had had a positive response to tamoxifen.  Eligible patients with measurable and non-measurable disease were randomized to receive either a single daily dose of 1 mg or 10 mg of ARIMIDEX  or megestrol acetate 40 mg four times a day.  The studies were double-blinded with respect to ARIMIDEX.  Time to progression and objective response (only patients with measurable disease could be considered partial responders) rates were the primary efficacy variables.  Objective response rates were calculated based on the Union Internationale Contre le Cancer (UICC) criteria.  The rate of prolonged (more than 24 weeks) stable disease, the rate of progression, and survival were also calculated.</p>
<p>Both trials included over 375 patients; demographics and other baseline characteristics were similar for the three treatment groups in each trial.  Patients in the 0005 trial had responded better to prior tamoxifen treatment.  Of the patients entered who had prior tamoxifen therapy for advanced disease (58% in Trial 0004; 57% in Trial 0005), 18% of these patients in Trial 0004 and 42% in Trial 0005 were reported by the primary investigator to have responded.   In Trial 0004, 81% of patients were ER-positive, 13% were ER-unknown, and 6% were ER-negative.  In Trial 0005, 58% of patients were ER-positive, 37% were ER-unknown, and 5% were ER-negative. In Trial 0004, 62% of patients had measurable disease compared to 79% in Trial 0005. The sites of <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> were similar among treatment groups for each trial.  On average, 40% of the patients had soft tissue <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>; 60% had bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>; and 40% had visceral (15% liver) <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>.</p>
<p>Efficacy results from the two studies were similar as presented in Table 13.  In both studies there were no significant differences between treatment arms with respect to any of the efficacy parameters listed in the table below.</p>
<a name="idf0646ea-544a-43f6-8547-91c2c2fe43b9"></a><table frame="hsides">
<caption><span>Table 13 â€“ Efficacy Results of Second-line Treatment</span></caption>
<colgroup>
<col width="106*">
<col width="98*">
<col width="96*">
<col width="98*">
</colgroup>
<thead><tr class="First Last">
<td align="left" valign="top"></td>
<td align="center" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">10 mg</span></p>
</td>
<td align="center" valign="top">
<p class="First"><span class="Bold">Megestrol</span></p>
<p><span class="Bold">Acetate</span></p>
<p><span class="Bold">160 mg</span></p>
</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Surviving Patients</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><p class="First">Trial 0004</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">(<span class="Underline">N. America</span>)</p></td>
<td align="center" valign="top"><p class="First">(N=128)</p></td>
<td align="center" valign="top"><p class="First">(N=130)</p></td>
<td align="center" valign="top"><p class="First">(N=128)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Median Follow-up (months)<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></p></td>
<td align="center" valign="top"><p class="First">31.3</p></td>
<td align="center" valign="top"><p class="First">30.9</p></td>
<td align="center" valign="top"><p class="First">32.9</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Median Time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (months)</p></td>
<td align="center" valign="top"><p class="First">29.6</p></td>
<td align="center" valign="top"><p class="First">25.7</p></td>
<td align="center" valign="top"><p class="First">26.7</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">2 Year Survival Probability (%)</p></td>
<td align="center" valign="top"><p class="First">62.0</p></td>
<td align="center" valign="top"><p class="First">58.0</p></td>
<td align="center" valign="top"><p class="First">53.1</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Median Time to Progression (months)</p></td>
<td align="center" valign="top"><p class="First">5.7</p></td>
<td align="center" valign="top"><p class="First">5.3</p></td>
<td align="center" valign="top"><p class="First">5.1</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">Objective Response</p>
<p>	(all patients) (%)</p>
</td>
<td align="center" valign="top"><p class="First">12.5</p></td>
<td align="center" valign="top"><p class="First">10.0</p></td>
<td align="center" valign="top"><p class="First">10.2</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Stable Disease for &gt;24 weeks (%)</p></td>
<td align="center" valign="top"><p class="First">35.2</p></td>
<td align="center" valign="top"><p class="First">29.2</p></td>
<td align="center" valign="top"><p class="First">32.8</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Progression (%)</p></td>
<td align="center" valign="top"><p class="First">86.7</p></td>
<td align="center" valign="top"><p class="First">85.4</p></td>
<td align="center" valign="top"><p class="First">90.6</p></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Trial 0005</p></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">(<span class="Underline">Europe, Australia, S. Africa</span>)</p></td>
<td align="center" valign="top"><p class="First">(N=135)</p></td>
<td align="center" valign="top"><p class="First">(N=118)</p></td>
<td align="center" valign="top"><p class="First">(N=125)</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Median Follow-up (months)<a href="#footnote-9" class="Sup">*</a></p></td>
<td align="center" valign="top"><p class="First">31.0</p></td>
<td align="center" valign="top"><p class="First">30.9</p></td>
<td align="center" valign="top"><p class="First">31.5</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Median Time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (months)</p></td>
<td align="center" valign="top"><p class="First">24.3</p></td>
<td align="center" valign="top"><p class="First">24.8</p></td>
<td align="center" valign="top"><p class="First">19.8</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">2 Year Survival Probability (%)</p></td>
<td align="center" valign="top"><p class="First">50.5</p></td>
<td align="center" valign="top"><p class="First">50.9</p></td>
<td align="center" valign="top"><p class="First">39.1</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Median Time to Progression (months)</p></td>
<td align="center" valign="top"><p class="First">4.4</p></td>
<td align="center" valign="top"><p class="First">5.3</p></td>
<td align="center" valign="top"><p class="First">3.9</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">Objective Response</p>
<p>	(all patients) (%)</p>
</td>
<td align="center" valign="top"><p class="First">12.6</p></td>
<td align="center" valign="top"><p class="First">15.3</p></td>
<td align="center" valign="top"><p class="First">14.4</p></td>
</tr>
<tr>
<td align="left" valign="top"><p class="First">Stable Disease for &gt;24 weeks (%)</p></td>
<td align="center" valign="top"><p class="First">24.4</p></td>
<td align="center" valign="top"><p class="First">25.4</p></td>
<td align="center" valign="top"><p class="First">23.2</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top"><p class="First">Progression (%)</p></td>
<td align="center" valign="top"><p class="First">91.9</p></td>
<td align="center" valign="top"><p class="First">89.8</p></td>
<td align="center" valign="top"><p class="First">92.0</p></td>
</tr>
</tbody>
</table>
<p>When data from the two controlled trials are pooled, the objective response rates and median times to progression and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were similar for patients randomized to ARIMIDEX 1 mg and megestrol acetate.  There is, in this data, no indication that ARIMIDEX 10 mg is superior to ARIMIDEX 1 mg.</p>
<a name="i3a4b31cb-5948-43be-8a0c-46e9150b21f7"></a><table frame="hsides">
<caption><span>Table 14 â€“ Pooled Efficacy Results of Second-line Treatment</span></caption>
<colgroup>
<col>
<col>
<col>
<col>
</colgroup>
<thead><tr class="First Last">
<td align="left" valign="top">
<p class="First"><span class="Bold">Trials 0004 &amp; 0005</span></p>
<p><span class="Bold">(Pooled Data)</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">N=263</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">ARIMIDEX</span></p>
<p><span class="Bold">10 mg</span></p>
<p><span class="Bold">N=248</span></p>
</td>
<td align="left" valign="top">
<p class="First"><span class="Bold">Megestrol Acetate</span></p>
<p><span class="Bold">160 mg</span></p>
<p><span class="Bold">N=253</span></p>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td align="left" valign="top">
<p class="First">Median Time to</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> (months)</p>
</td>
<td align="left" valign="top"><p class="First">26.7</p></td>
<td align="left" valign="top"><p class="First">25.5</p></td>
<td align="left" valign="top"><p class="First">22.5</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">2 Year Survival</p>
<p>Probability (%)</p>
</td>
<td align="left" valign="top"><p class="First">56.1</p></td>
<td align="left" valign="top"><p class="First">54.6</p></td>
<td align="left" valign="top"><p class="First">46.3</p></td>
</tr>
<tr>
<td align="left" valign="top">
<p class="First">Median Time to</p>
<p>Progression</p>
</td>
<td align="left" valign="top"><p class="First">4.8</p></td>
<td align="left" valign="top"><p class="First">5.3</p></td>
<td align="left" valign="top"><p class="First">4.6</p></td>
</tr>
<tr class="Last">
<td align="left" valign="top">
<p class="First">Objective Response</p>
<p>(all patients) (%)</p>
</td>
<td align="left" valign="top"><p class="First">12.5</p></td>
<td align="left" valign="top"><p class="First">12.5</p></td>
<td align="left" valign="top"><p class="First">12.3</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">These tablets are supplied in bottles of 30 tablets (<span class="Bold">NDC 54868-5000-0</span>).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at controlled room temperature, 20-25Â°C (68-77Â°F) [see USP].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>â€œsee FDA Approved Patient Labelingâ€?<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2>17.1 Pregnancy</h2>
<p class="First">Patients should be advised that ARIMIDEX may cause fetal harm.  They should also be advised that ARIMIDEX is not for use in premenopausal women; therefore, if they become pregnant, they should stop taking ARIMIDEX and immediately contact their doctor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<h2>17.2 Allergic (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>) Reactions</h2>
<p class="First">Patients should be informed of the possibility of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue and/or throat (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) which may cause difficulty in swallowing and/or breathing and to immediately report this to their doctor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<h2>17.3 Ischemic Cardiovascular Events</h2>
<p class="First">Patients with pre-existing <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> should be informed that an increased incidence of cardiovascular events has been observed with ARIMIDEX use compared to tamoxifen use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.4"></a><p></p>
<h2>17.4 Bone Effects</h2>
<p class="First">Patients should be informed that ARIMIDEX lowers the level of estrogen.  This may lead to a loss of the mineral content of bones, which might decrease bone strength.  A possible consequence of decreased mineral content of bones is an increase in the risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></h2>
<p class="First">Patients should be informed that an increased level of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> might be seen while receiving ARIMIDEX.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.6"></a><p></p>
<h2>17.6 Tamoxifen</h2>
<p class="First">Patients should be advised not to take ARIMIDEX with Tamoxifen.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">FDA-Approved Patient Labeling</span></p>
<p>PATIENT INFORMATION</p>
<p>  ARIMIDEX<span class="Sup">Â®</span></p>
<p>(<span class="Italics">anastrozole)</span> (an as' troe zole) </p>
<p>Tablets </p>
<p> Read the information that comes with ARIMIDEX before you start taking it and each time you get a refill.  The information may have changed.  This leaflet does not take the place of talking with your doctor about your medical condition or treatment.  Talk with your doctor about ARIMIDEX when you start taking it and at regular checkups.</p>
<p><span class="Bold">What is ARIMIDEX? </span></p>
<p>ARIMIDEX is a prescription medicine used in women who have finished <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (â€œthe change of lifeâ€?) for:  </p>
<ul>
<li>
<p class="First">treatment of early breast cancer</p>
<ul>
<li><p class="First">after surgery, with or without radiation</p></li>
<li><p class="First">in women whose breast cancer is hormone receptor-positive</p></li>
</ul>
</li>
<li><p class="First">first treatment of locally advanced or metastatic breast cancer, in women whose breast cancer is hormone receptor-positive or the hormone receptors are not known.</p></li>
<li><p class="First">treatment of advanced breast cancer, if the cancer has grown, or the disease has spread after tamoxifen therapy.</p></li>
</ul>
<p>ARIMIDEX does not work in women with breast cancer who have not finished <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (premenopausal women).</p>
<p><span class="Bold">Who should not take ARIMIDEX? </span></p>
<p>Do not take ARIMIDEX if you: </p>
<ul>
<li><p class="First">are pregnant, think you may be pregnant, or plan to get pregnant.  ARIMIDEX may harm your unborn child. If you become pregnant while taking ARIMIDEX, tell your doctor right away.</p></li>
<li><p class="First">have not finished <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (are premenopausal).</p></li>
<li><p class="First">are allergic to any of the ingredients in ARIMIDEX. See the end of this leaflet for a list of the ingredients in ARIMIDEX.</p></li>
<li><p class="First">are a man or child.</p></li>
</ul>
<p><span class="Bold">What is the most important information I should know about ARIMIDEX?    </span></p>
<p>ARIMIDEX may cause serious side effects including:  </p>
<ul>
<li>
<p class="First"><span class="Bold">Heart disease.  </span>Women with early breast cancer, who have a history of blockages in heart arteries (<span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>) and who take ARIMIDEX may have a slight increase in this type of heart disease compared to similar patients who take tamoxifen.</p>
<ul><li><p class="First">Stop taking ARIMIDEX and call your doctor right away if you have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>. These can be symptoms of heart disease.</p></li></ul>
</li>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> (bone softening and weakening).</span>  ARIMIDEX lowers estrogen in your body, which may cause your bones to become softer and weaker.  This can increase your chance of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, specifically of the spine, hip and wrist. Your doctor may order a test for you called a bone mineral density study before you start taking ARIMIDEX and during treatment with ARIMIDEX as needed.</p></li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking ARIMIDEX?</span></p>
<p><span class="Bold">ARIMIDEX may not be right for you.  Before taking ARIMIDEX, tell your doctor about all your medical conditions, including if you: </span></p>
<ul>
<li><p class="First">have not finished <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.  Talk to your doctor if you are not sure.  See â€œWho should not take ARIMIDEX?â€?</p></li>
<li><p class="First">have had a previous heart problem</p></li>
<li><p class="First">have a condition called <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span></p></li>
<li><p class="First">have high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></p></li>
<li><p class="First">are pregnant, planning to become pregnant, or breast feeding.  See â€œWho should not take ARIMIDEX?â€?</p></li>
<li><p class="First">are nursing a baby. It is not known if ARIMIDEX passes into breast milk.  You and your doctor should decide if you will take ARIMIDEX or breast feed. You should not do both.</p></li>
</ul>
<p>Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Especially tell your doctor if you take: </p>
<ul>
<li><p class="First"><span class="Bold">Tamoxifen. </span> You should not take <span class="Bold">ARIMIDEX</span> with tamoxifen. Taking tamoxifen with ARIMIDEX may lower the amount of ARIMIDEX in your blood and may cause ARIMIDEX not to work as well.</p></li>
<li>
<p class="First"><span class="Bold">Medicines containing estrogen. </span>ARIMIDEX may not work if taken with one of these medicines:</p>
<ul>
<li><p class="First">hormone replacement therapy</p></li>
<li><p class="First">birth control pills</p></li>
<li><p class="First">estrogen creams</p></li>
<li><p class="First">vaginal rings</p></li>
<li><p class="First">vaginal suppositories</p></li>
</ul>
</li>
</ul>
<p>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist each time you get a new medicine.</p>
<p><span class="Bold">How should I take ARIMIDEX? </span></p>
<ul>
<li><p class="First">Take ARIMIDEX exactly as prescribed by your doctor.  Keep taking ARIMIDEX for as along as your doctor prescribes it for you.</p></li>
<li><p class="First">Take one ARIMIDEX tablet each day.</p></li>
<li><p class="First">ARIMIDEX can be taken with or without food.</p></li>
<li><p class="First">If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Take your next regularly scheduled dose. Do not take two doses at the same time.</p></li>
<li><p class="First">If you have taken more ARIMIDEX than your doctor has prescribed, contact your doctor right away. Do not take any additional ARIMIDEX until instructed to do so by your doctor.</p></li>
</ul>
<p>Talk with your doctor about any health changes you have while taking ARIMIDEX. </p>
<p><span class="Bold">What are possible side effects of ARIMIDEX?  </span></p>
<p>ARIMIDEX can cause serious side effects including:  </p>
<ul>
<li><p class="First">See â€œ<span class="Bold">What is the most important information I should know about ARIMIDEX</span>?â€?</p></li>
<li><p class="First"><span class="Bold">increased blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood). </span> Your doctor may check your <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> while you take ARIMIDEX therapy.</p></li>
<li><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. </span> Stop taking ARIMIDEX and call your doctor right away if you get any <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesions</span>, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>.</p></li>
<li>
<p class="First"><span class="Bold">severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span>  Get medical help right away if you have:</p>
<ul>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, tongue, or throat.</p></li>
<li><p class="First">trouble swallowing</p></li>
<li><p class="First">trouble breathing</p></li>
</ul>
</li>
<li>
<p class="First"><span class="Bold">liver problems.</span>  ARIMIDEX can cause <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the liver and changes in blood tests of the liver function.  Your doctor may monitor you for this. Stop taking ARIMIDEX and call your doctor right away if you have any of these signs or symptoms of a liver problem:</p>
<ul>
<li><p class="First">a general feeling of not being well</p></li>
<li><p class="First">yellowing of the skin or whites of the eyes</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> on the right side of your abdomen</p></li>
</ul>
</li>
</ul>
<p>Common side effects in women taking ARIMIDEX include: </p>
<ul>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="380094" conceptname="Carpal tunnel syndrome">carpal tunnel syndrome</span> (<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in parts of the hand)</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span></p></li>
<li><p class="First">high blood pressure</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p></li>
<li><p class="First">thinning of the hair (<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span>)</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep problems</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></p></li>
<li><p class="First">increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="435839" conceptname="Lymphedema">lymphedema</span> (build up of lymph fluid in the tissues of your affected arm)</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="77965" conceptname="Acquired trigger finger">trigger finger</span> (a condition in which one of your fingers or your thumb catches in a bent position)</p></li>
</ul>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.  </p>
<p><span class="Bold">HOW SHOULD I STORE ARIMIDEX?</span></p>
<ul>
<li><p class="First">Store ARIMIDEX at 68Â°F to 77Â°F (20Â°C to 25Â°C).</p></li>
<li><p class="First">Keep ARIMIDEX and all medicines out of the reach of children.</p></li>
</ul>
<span class="Bold">General information about ARIMIDEX. </span><p></p> Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take ARIMIDEX for a condition for which it was not prescribed. Do not give ARIMIDEX to other people, even if they have the same symptoms you have. It may harm them.  <p></p>This patient information leaflet summarizes the most important information about ARIMIDEX. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ARIMIDEX that is written for health professionals. For more information call 1-866-992-9276 or go to www.ARIMIDEX.com.  <p><span class="Bold">What are the ingredients in ARIMIDEX? </span></p>Active ingredient: anastrozole <p>Inactive ingredients: lactose, magnesium stearate, hydroxypropylmethylcellulose, polyethylene glycol, povidone, sodium starch glycolate, and titanium dioxide.</p>
<p>ARIMIDEX is a registered trademark of the AstraZeneca group of companies. Â©2009 AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. All rights reserved. </p>
<p>35303â€“XX</p>
<p>Rev 04/2011</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First">Additional barcode labeling by:<br>Physicians Total Care, inc.<br>Tulsa, OklahomaÂ Â Â Â Â Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"></p>
<div class="Figure"><img alt="Arimidex 1mg - 30 tablet count bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4fee8d4c-bb21-4773-b622-87f9a4ff333a&amp;name=5000.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ARIMIDEXÂ 		
					</strong><br><span class="contentTableReg">anastrozole tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5000(NDC:0310-0201)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANASTROZOLE</strong> (ANASTROZOLE) </td>
<td class="formItem">ANASTROZOLE</td>
<td class="formItem">1Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (logo consisting of a letter A (upper case) with an arrowhead attached to the foot of the extended right leg of the A) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">adx1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5000-0</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020541</td>
<td class="formItem">02/19/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c6d0f6d9-ea38-469c-b961-0fce271fb349</div>
<div>Set id: 4fee8d4c-bb21-4773-b622-87f9a4ff333a</div>
<div>Version: 2</div>
<div>Effective Time: 20120201</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
